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Abstract 
 
Where one lives affects one’s blood pressure. Observational studies demonstrate 
that living in communities of low socioeconomic status is associated with higher blood 
pressure and worse cardiovascular outcomes. In understanding the reasons for these 
disparities, a key question is whether evidence-based antihypertensive medication therapy 
is less effective in lowering blood pressure and improving cardiovascular outcomes in 
lower socioeconomic communities. If so, then anti-hypertensive therapies derived from 
randomized clinical trials (RCTs) may be suboptimal in achieving expected outcomes. 
Despite standardized protocols and balancing of demographic and clinical characteristics 
between study arms of RCTs, the socioeconomic environment in which people live is 
rarely examined, potentially exerting an unmeasured effect on study outcomes.  
To determine the impact of socioeconomic context on response to 
antihypertensive medication in clinical trials, we analyzed data from the Antihypertensive 
and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), the largest 
existing RCT of hypertension treatment. This trial, conducted from 1994 to 2002, 
randomized 42,418 people, 55 years or older, with hypertension and at least one other 
cardiovascular risk factor, to chlorthalidone, lisinopril, amlodipine or doxazosin (mean 
follow-up of 4.9 years). After excluding non-continental U.S. sites and the doxazosin arm 
(terminated early in ALLHAT) our study included 27,862 participants. We defined 
socioeconomic context by mapping study site ZIP codes to counties and stratifying these 
counties into income quintiles based on the national distribution of county median 
household income, adjusted for cost-of-living, from the 2000 U.S. census. 
We compared baseline and clinical characteristics, visit and medication 
adherence, blood pressure control, and cardiovascular outcomes between ALLHAT 
participants in the lowest and highest income sites using multivariable regression models. 
Participants receiving care in Quintile 1 (Q1, lowest income sites) (n = 2169, 7.8%) were 
more likely to be female, black, Hispanic, have fewer total years of education, live in the 
South, and have fewer cardiovascular risk factors than participants in Quintile 5 (Q5, 
highest income sites) (n = 10458, 37.6%). Compared with Q5, participants in Q1 were 
less likely to achieve blood pressure control (<140/90 mmHg) (OR, 0.48; 95% CI, 0.37-
0.63), and experienced higher all-cause mortality (HR, 1.25; 95% CI, 1.10-1.41), heart 
failure hospitalizations or mortality (HR, 1.26; 95% CI, 1.03-1.55) and end-stage renal 
disease (ESRD) (HR, 1.86; 95% CI, 1.26-2.73), though lower angina hospitalizations 
(HR, 0.70; 95% CI, 0.59-0.83) and coronary revascularization (HR, 0.71; 95% CI, 0.57-
0.89). There were no differences in stroke, myocardial infarction, or peripheral arterial 
disease.  
Despite having access to standardized treatment protocols, participants in the 
lowest income sites experienced poorer blood pressure control, higher mortality, ESRD 
and heart failure morbidity, and decreased coronary revascularization compared to those 
in the highest income sites. These findings suggest a need to better measure and bolster 
the socioeconomic context beyond the medical environment to eliminate disparities in 
outcomes for RCTs of antihypertensive medications. Understanding these relationships 
may guide the generalizability of RCT findings, promote the assessment of participants’ 
socioeconomic context in clinical trials and hypertension treatment guidelines, and 
inform broader strategies for combating hypertension in populations living in low 
socioeconomic environments. 
 
  
Acknowledgements 
 
My interest in medicine was sparked early in life by the difficulties my young 
immigrant family encountered in attempting to access high-quality health care. As I grew 
older and realized that the health care delivered in the real world was often not equitable, 
I resolved to become a culturally competent physician who worked to address disparities 
in health care, and discovered that one way in which I could accomplish this goal was 
through research. However, when I first entered medical school, I had virtually no 
clinical research experience. Fortunately, I was lucky enough to connect with a great 
mentor, and in the ensuing years, as I acquired the clinical knowledge and skills I would 
need to become a physician, I concurrently learned how to think through clinical research 
problems. This thesis, which draws from research that I conducted during my fifth year, 
marks the culmination of my transformation into a clinical researcher. In the process, I 
have also discovered my passion for research that has the potential to shape health care 
policy and confront the health disparities that plague this country.   
Research, like medicine, is a team sport. The work presented here would not be 
possible without the support, help, and guidance of numerous team players. 
I would first and foremost like to thank Dr. Erica Spatz, my amazing mentor of 
four years, and one of my first and most inspiring physician role models. Thank you for 
taking a chance on me four years ago, for offering calm guidance and wisdom when I did 
not know what to do, for teaching me how to develop and investigate clinical research 
questions in a thorough and critical way, for teaching me about work-life balance, for 
helping me become a better scientific writer, for responding to my late-night emails with 
even later emails, and for showing me through your own clinical practice that practicing 
medicine in a patient-centered way is not only possible, but absolutely necessary.  
I would like to thank our statistical wizard, Dr. Jeph Herrin for his patience and 
skill in helping us navigate difficult statistical analyses. I would like to thank Dr. Sanket 
Dhruva, Dr. Nihar Desai, and Dr. Harlan Krumholz, for supporting this project since its 
inception and offering their valuable feedback throughout. I would also like to thank Dr. 
Barry Davis and Sara Pressel for collaborating with us and sharing data from ALLHAT 
with us (as well as providing feedback), and Tara Liptak for helping us acquire the data. 
I would like to especially thank my MD/MHS thesis committee – Dr. Nihar 
Desai, Dr. Julie Goodwin, Dr. Shuta Ishibe and Dr. Erica Spatz  – for providing the 
crucial advice that led to the development of the final methodology presented here and 
for contributing their feedback for this thesis. I would like to thank the Office of Student 
Research at the Yale School of Medicine for supporting all of my research activities 
during my time at Yale. This work was funded by the National Institutes of Health-
National Heart, Lung & Blood Institute Award and the Richard K. Gershon M.D. Student 
Research Fellowship.  
I would also like to thank my parents, Milena and Agron Shahu, for being 
courageous enough to transplant our family from Albania to the United States, for 
instilling in me the importance of work ethic, and for teaching me to lead a life of 
integrity. Last, I would like to thank my little sister, Anja Shahu, for designing Figure 1 
and for helping me realize when I was only 10 years old that I liked taking care of others.
  
Table of Contents 
Foreword ............................................................................................................................. 1	
Introduction ......................................................................................................................... 2	
Beyond the guidelines: new paradigms in treatment of hypertension ............................ 2	
Socioeconomic context and hypertension outcomes ..................................................... 12	
The Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial .. 15	
Statement of purpose ........................................................................................................ 19	
Methods ............................................................................................................................ 20	
Contributions ................................................................................................................ 20	
Overview ....................................................................................................................... 20	
ALLHAT study design and organization ....................................................................... 21	
Income data ................................................................................................................... 23	
Exclusion criteria .......................................................................................................... 23	
Outcomes ....................................................................................................................... 24	
Statistical Analysis ........................................................................................................ 25	
Results ............................................................................................................................... 27	
Geographic distribution of clinical sites ....................................................................... 27	
Baseline characteristics ................................................................................................ 28	
Visit and medication adherence .................................................................................... 30	
Blood pressure control .................................................................................................. 31	
Cardiovascular outcomes ............................................................................................. 38	
Discussion ......................................................................................................................... 50	
Limitations .................................................................................................................... 56	
Conclusions ................................................................................................................... 57	
References ......................................................................................................................... 60	
 
 1 
Foreword 
 
This research was conducted during my time as a medical student at the Yale School of 
Medicine, with investigators in the Center for Outcomes Research & Evaluation, and in 
collaboration with original investigators from the Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial (ALLHAT). As the lead author, I presented our 
findings at the American Heart Association (AHA) Council on Hypertension/AHA 
Council on Kidney in Cardiovascular Disease/American Society of Hypertension/Joint 
Scientific Sessions 2017, where it was accepted as an oral presentation and received the 
AFHRE Travel Award for Patient-Oriented or Clinical Research in Hypertension. A 
manuscript is in preparation for submission for publication in the biomedical literature. 
 
Shahu A, Herrin J, Dhruva SS, Desai NR, Krumholz HM, Spatz ES. Abstract 148: 
Association of Socioeconomic Context with Blood Pressure Response and 
Cardiovascular Outcomes in ALLHAT. Hypertension. 2017;70(Suppl 1):A148-A. 
(Abstr.) 
Also presented as a poster, under the title: Variation in Blood Pressure Response 
and Cardiovascular Outcomes by Socioeconomic Context in ALLHAT. Medical 
Student Research Day, Yale School of Medicine, New Haven, CT, 2017. 
 
Shahu A, Herrin J, Dhruva SS, Desai NR, Pressel SL, Davis BR, Krumholz HM, Spatz 
ES. Association of Socioeconomic Context with Response to Antihypertensive 
Medication in ALLHAT. (in preparation for submission) 
 2 
Introduction 
 
Beyond the guidelines: new paradigms in treatment of hypertension  
 Hypertension, a medical condition wherein arterial blood pressure is persistently 
elevated, is one of the most prevalent medical conditions in the world. It is the most 
common condition seen in primary care offices and poses a significant public health 
challenge, with an estimated global prevalence of 24.6% in 2000 in people aged 20 years 
and older, and projections of up to 29.2% in 2025 (1, 2). In the U.S., the prevalence of 
hypertension among adults remained stable from 1999 to 2014 (at about 29%), and the 
prevalence of controlled hypertension in adults increased from 31.5% to 53.3% from 
1999 to 2009; however, in the years since, the proportion of people with controlled 
hypertension has plateaued (3). These statistics indicate that while some progress has 
been made over the years in treating hypertension, there remains considerable room for 
improvement, with millions of Americans still in need of improved blood pressure 
control. 
 Moreover, hypertension also plays a causative role in cardiovascular disease 
(myocardial infarction, stroke, heart failure, peripheral vascular disease) as well as renal 
disease, and inadequate treatment has been associated with increased mortality (4). 
Furthermore, countless studies have shown that treatment of hypertension is vitally 
important. For every 10-mmHg reduction in systolic blood pressure (SBP), there is a 22% 
reduction in the rates of major cardiovascular disease events, coronary heart disease, 
stroke, heart failure, and all-cause mortality (5, 6).  
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 However, despite the large, well-documented body of evidence emphasizing the 
importance and benefits of antihypertensive treatment, the medical community has long 
debated thresholds for defining hypertension, modalities for diagnosis and treatment of 
hypertension, as well as blood pressure targets. In an effort to standardize treatment for a 
common but treatable condition, the first clinical practice guidelines for the treatment of 
hypertension were developed in 1977 by the Joint National Committee (JNC) on 
Detection, Evaluation, and Treatment of High Blood Pressure, appointed by the National, 
Heart, Lung and Blood Institute (NHLBI) (7). This committee of experts offered six key 
recommendations in a consensus document, based on a combination of existing evidence 
and expert opinion: 1) anyone evaluating blood pressure should have resources available 
for referral, confirmation, and follow-up; 2) antihypertensive therapy should be started in 
all adults with a diastolic blood pressure (DBP) of 105 mmHg or greater; 3) adults with 
DBP between 90 and 104 mmHg should be treated on a case-by-case basis depending on 
their cardiovascular risk factors; 4) evaluation of hypertension could usually be limited to 
a few baseline tests; 5) providers should take a cost-effective stepped-care approach to 
treatment (i.e. begin treatment with one drug, titrate to maximal dose, and add additional 
drugs in a step-wise fashion if therapeutic goal is not achieved); and 6) providers should 
make plans with patients for long-term control of blood pressure (8). Although existing 
data suggested an increased risk from elevated SBP, no recommendations were made 
regarding SBP in order to minimize complexity in the guidelines. 
 Clinical practice guidelines for hypertension management were updated over the 
ensuing decades, becoming increasingly comprehensive thanks to evidence from major 
observational studies and large clinical trials of antihypertensive medications. Thresholds 
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for diagnosis of hypertension grew more stringent, leading to the JNC 7 guidelines, 
published in 2003, which defined hypertension in adults as having an average SBP of 140 
mmHg or greater or DBP of 90 mmHg or greater (9). Prehypertension was defined as 
having an average SBP between 130 and 139 mmHg or DBP between 80 and 89 mmHg. 
Greater emphasis was placed on standardization of methods; for example, it was 
recommended that office blood pressure be measured with the patient in a seated position 
after resting for 5 minutes (9). Lifestyle modifications were recommended for early 
treatment of prehypertension or hypertension. Step-wise treatment with antihypertensive 
medications was recommended at a threshold of 140 mm Hg SBP or 90 mm Hg DBP 
(with a treatment goal of <130/80 mmHg for patients with diabetes and chronic kidney 
disease [CKD]), recognizing that many people would likely need more than one 
medication. Thiazide diuretics (e.g., chlorthalidone or hydrochlorothiazide) were 
recommended as first-line medications, although other medications were also deemed 
effective in patients with additional cardiovascular risk: calcium channel blockers (CCBs, 
e.g., amlodipine), and angiotensin-converting-enzyme inhibitors (e.g., lisinopril), 
angiotensin receptor blockers (ARBs, e.g., losartan), and beta blockers (e.g., metoprolol). 
These recommendations were strongly influenced by findings from the then-recent 
randomized clinical trial (RCT) titled Antihypertensive and Lipid-Lowering Treatment to 
Prevent Heart Attack Trial (ALLHAT, described in detail later) (10).  
However, about a decade later, some experts questioned the strength of the 
evidence supporting the blood pressure treatment recommendations in JNC 7. Moreover, 
the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, found that a 
more intensive treatment target of 120/80 mmHg, versus the standard 140/90 mmHg in 
 5 
low-risk people with diabetes, did not reduce cardiovascular outcomes (11). This led to 
the convening of a new guideline committee (JNC 8), which focused their review on 3 
questions: does initiating hypertension treatment at specific blood pressure thresholds 
improve outcomes; does treating blood pressure to specific blood pressure targets 
improve outcomes; and do antihypertensive medications differ in their comparative 
benefits and harms on health outcomes (12). In alignment with the evidence, the 
published guidelines recommended a treatment threshold of 150/90 mmHg in patients 60 
years or older, and 140/90 mmHg for adults younger than 60 years. They determined that 
based on the negative trial results of ACCORD and the absence of other data sources, 
there was insufficient evidence to support lower treatment targets in people over 60 years 
of age, and younger people with CKD or diabetes; this represented a break from past 
guidelines and concurrent clinical practice (12). Additionally, after reevaluation of 
clinical trial data, thiazide diuretics, ACE inhibitors/ARBs, and calcium channel blockers 
were equally recommended as first-line agents, though CCBs and thiazides were 
recommended as first-line agents in black adults. The JNC 8 guidelines resulted in 
considerable controversy. Critics argued that the absence of data to support more 
stringent SBP targets did not necessarily point to an absence of effect, and that until new 
data were generated, guideline committees should offer their expert opinion and 
providers should use their own clinical judgment when helping patients make decisions 
about hypertension treatment (4, 13). It is unknown whether the JNC 8 guidelines had an 
impact on clinical practice or outcomes; they were again updated only three years later.  
 Just after the JNC 8 guidelines were published, the results of two trials of 
antihypertensive medications were reported: the Systolic Blood Pressure Intervention 
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Trial (SPRINT) and the Heart Outcomes Prevention Evaluation (HOPE)–3 trial (14). 
SPRINT enrolled people aged 50 or older at high risk for cardiovascular disease but 
without diabetes or prior stroke, and found that patients randomized to a treatment SBP 
goal of 120 mmHg experienced fewer cardiovascular events as well as a survival benefit 
compared to patients treated to a SBP goal of 140 mmHg (15). HOPE-3 enrolled men 
aged 55 or older and women aged 65 or older with an intermediate 10-year risk for 
cardiovascular events but no cardiovascular disease, and found that antihypertensive 
therapy was not associated with a lower risk of adverse cardiovascular events, as 
compared to treatment with a placebo, though benefit was observed in the subgroup in 
the highest tertile of baseline systolic blood pressure (16). As, a result, there was a push 
to revisit the guidelines.   
In response, a joint task force, led by the American College of Cardiology (17) 
and American Heart Association (AHA) and including 11 different medical 
organizations, assumed the role of developing new guidelines from the NHLBI. In the 
most comprehensive hypertension guidelines ever, which were more focused around 
class of recommendation and the level of existing evidence, this task force made 106 
recommendations on the basis of an extensive systematic literature review (18, 19). 
Among them, a blood pressure below systolic of 120 mmHg and diastolic <80 mmHg 
was categorized as normal, systolic blood pressure of 120-129 and a diastolic blood 
pressure <80 mmHg was categorized as “elevated,” 130-139 mmHg or 80-89 mmHg was 
categorized as stage 1 hypertension, and ³140/90 mmHg was categorized as stage 2 
hypertension (20). These classifications were reminiscent of the JNC 7 taxonomy, 
acknowledging observational data that the risks associated with hypertension start with 
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an SBP as low as 110-115 mmHg (2). Moreover, in somewhat of a reversal from the JNC 
8 guidelines, antihypertensive medication was recommended for patients with an 
estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk of 10% or higher 
and an SBP ³130 mmHg or DBP ³80 mmHg. Additional emphasis was also placed on 
out-of-office blood pressure monitoring (home-based monitoring and 24-hour ambulatory 
blood pressure monitoring) and nonpharmacological interventions (21).  
These new guidelines promise to radically alter the landscape of hypertension 
diagnosis and treatment. If they are incorporated into clinical practice, the impact would 
be massive: the prevalence of U.S. adults diagnosed with hypertension would increase 
from 31.9% to 45.6%, and among U.S. adults taking blood pressure-lowering medication, 
the proportion of people with blood pressure above goal would increase from 39.0% to 
54.3% (22). Among U.S. adults aged 45-75, the prevalence of hypertension would rise to 
63.0% (70.1 million people). In other countries such as China, the impact would be even 
greater, with prevalence rates increasing from 38.0% to 55.0% (23). These statistics 
indicate that more people than ever, especially younger adults, would be considered to 
have hypertension, to be eligible for antihypertensive medication, and to potentially 
require more intensive blood pressure lowering.   
With millions of additional Americans newly labeled as having hypertension, the 
2017 guidelines raise new concerns about the shortcomings of hypertension management 
in the modern medical era. First, even among guidelines produced by different medical 
organizations, there is inconsistency. In 2017, the American College of Physicians (ACP) 
and American Academy of Family Physicians (ACP/AAFP) recommended that patients 
be treated to a goal SBP of 140 or 150 mmHg, depending on age and level of 
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cardiovascular risk (24). This disagreement among professional organizations may lead 
to additional confusion among clinicians as well as patients. More aggressive 
antihypertensive treatment, some experts say, may result in more adverse events– such as 
syncope and renal dysfunction – as observed in SPRINT and ACCORD (11, 15, 25). 
Moreover, the risk of adverse events observed in SPRINT may be much greater in 
clinical practice, since in this trial, blood pressure measurements were attained under 
ideal conditions (and thus a target of 120/80 mmHg may represent the lowest possible 
blood pressure achieved); targeting 120/80 mmHg using more traditional methods to 
measure BP may result in even lower blood pressures and thus, more adverse events (21, 
26). Additionally, the burden associated with increasing prescriptions and pill numbers 
may not be considered ‘worth it’ to patients, many of whom are already overwhelmed by 
polypharmacy (27). For these reasons and others, it is unclear whether the new guidelines 
will result in changes in clinical practice. Historically, there are considerable gaps 
between guideline recommendations and clinical practice – perhaps because physicians 
are unfamiliar with the guidelines, find them impractical to implement in real life, or do 
not agree with the recommendations based on their own clinical experience (28). Other 
patient- and system-level factors may also impact guideline adoption. 
Perhaps most importantly, however, guidelines should be considered to provide 
just that – guidance. No matter how comprehensive they are, they are not intended to be 
adopted by everyone. By nature, guidelines will always be reductive in that they can 
never truly capture the unique combination of medical, personal, and contextual factors 
that should be considered in clinical decision making. Guidelines have transformed 
medicine to where it is today. They may be helpful in establishing proper methods of 
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blood pressure measurement or diagnosis of hypertension, or offering guidance on 
approaches to treatment of hypertension. Yet, guidelines alone will not be enough to 
reduce the prevalence of hypertension, improve rates of hypertension control, or further 
reduce cardiovascular outcomes resulting from hypertension. Debate around what 
specific blood pressure goals should be, as well as how these goals should differ and what 
medications are optimal for different patient populations will persist, which is why we 
must move beyond the guidelines in order to break new ground in the fight against 
hypertension, especially given the global impact of hypertension on cardiovascular 
outcomes.  
In order to make further progress in the treatment of hypertension, future 
approaches will need to incorporate precision-based medicine, personalized decision-
making, and contextual factors contributing to health disparities. In recent years, as 
methods to analyze “big data” have improved, new studies have attempted to develop 
more personalized approaches to antihypertensive treatment, namely by developing 
methods to better characterize heterogeneity in outcomes from large RCTs of 
hypertension. One study used advanced modeling techniques to examine heterogeneity in 
response to blood pressure treatment in the first 6 months of ALLHAT and discovered 
two distinct blood pressure trajectory patterns: immediate responders whose blood 
pressure decreased immediately following the start of the trial, and non-immediate 
responders whose blood pressure initially rose before declining following the start of 
treatment (29). These data may be important for expectation setting and planning 
appropriate follow-up. Other studies used patient-level data from SPRINT to develop 
prediction models that could allow providers to tailor the intensity of blood pressure 
 10 
treatment to the calculated risk and benefit for an individual patient or for a subgroup of 
patients (30, 31). By developing a better understanding of how different populations 
respond to different medications and developing personalized estimates of risks and 
benefits, we may be better able to tailor blood pressure goals and treatment for each 
individual rather than implementing a one-size-fits-all approach. 
The decision-making process offers yet another opportunity to further personalize 
treatment of hypertension. Principles of shared decision-making – which has become 
more important in recent years as medicine has shifted away from paternalism and 
physician-led decision-making – encourage patients who so desire to take an active role 
in their clinical care (32). In sharing with patients the range of reasonable treatment 
options, the associated risks and benefits of treatment, and the prognosis with and without 
intervention, patients can develop more informed preferences and treatment goals (33). 
Here again guidelines fall short in that practically speaking not all patients may be able to 
tolerate equally intensive blood pressure lowering or may even seek the same outcome 
out of treatment. For some patients, pill-taking is difficult and burdensome – the act of 
swallowing pills may even be difficult – making some patients more reluctant than others 
to take medications (34). One study found that patients may differ in the disutility (or 
burden) they associate with taking an idealized version of statin medications, and that for 
some patients this disutility may outweigh the benefits they would receive in lifetime 
gain (35). We are currently conducting a similar study using an idealized 
antihypertensive medication to better understand the disutility patients associate with 
blood pressure-lowering interventions. By using guidelines as a starting point for making 
clinical decisions that are more in line with patients’ values, clinicians can empower 
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patients to meet their own goals instead of setting them up for failure and difficulties with 
medication adherence. 
Last, differences in hypertension and hypertension outcomes between different 
people are not dependent solely on individual characteristics. While the approaches 
described above are important, as with the guidelines, they focus only on targeting factors 
at the individual level, and do little to address the community-level factors that contribute 
to prevalent disparities in hypertension, blood pressure control, and cardiovascular 
outcomes. In order for true progress to be made, we must develop new methods to 
investigate and address the contextual factors in which people live and obtain care. Such 
contextual factors – socioeconomic status or context, access to school or level of 
education, poverty, neighborhood violence, unemployment, access to healthy foods and 
exercise, social cohesion, and more – are known to worsen disparities in health outcomes 
(36-41). However, in the key studies (i.e. RCTs) used to develop guidelines, calculate 
risks and benefits, and base clinical decisions, little attention has been given to how 
contextual factors affect outcomes. Until we better characterize these factors, we may 
never be able to fully generalize outcomes from clinical studies or mitigate the burden of 
hypertension. We have selected one of the most studied contextual factors – 
socioeconomic context – in order to better understand how it may impact outcomes from 
important studies of hypertension. This will be the main subject of the remainder of this 
thesis. 
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Socioeconomic context and hypertension outcomes 
Where one lives affects one’s health. People living in communities of lower 
socioeconomic status historically have had lower income, worse housing, poorer access 
to nutrition, more environmental risks, and lower educational or job opportunities, than 
their counterparts living in wealthier areas (42). Additionally, studies dating back to the 
1980s have shown that people living in these communities experience poorer health and 
greater mortality (43, 44). In recent decades, socioeconomic disparities in various health 
outcomes have only widened – as measured by differences in median household income, 
education level, median housing value, housing occupancy, education level, occupation, 
and to some extent, race – suggesting that interventions to improve social risk factors 
may result in more equitable outcomes (45-48). 
Notably, the effect of the socioeconomic context of a neighborhood, community, 
or county on health outcomes is distinct from that of an individual’s socioeconomic 
status. Studies have demonstrated that neighborhood– or area–level socioeconomic 
deprivation, measured by a combination of factors such as housing indicators, wealth and 
income, education, and occupation, leads to worse health outcomes (e.g. incidence of 
heart failure, hospital readmissions for heart failure, cancer incidence and mortality, all-
cause mortality, depression, type 2 diabetes), even after accounting for individual-level 
factors such as individual socioeconomic status (39, 49-53). These findings suggest that 
person-level factors alone cannot explain disparities in health outcomes, perhaps because 
indicators such as area-level income may give a sense of both an individual’s general 
socioeconomic status as well as the amount of resources available to the overall 
community living in an area. Furthermore, these results underline the need to more 
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closely examine the impact that community-level factors such as socioeconomic context 
may have on the overall health and well-being of diverse populations. 
Where one lives also affects one’s blood pressure. Studies consistently show an 
inverse relationship between socioeconomic status and mean blood pressure (54-56). 
Moreover, numerous observational studies demonstrate that living in a neighborhood of 
lower socioeconomic status is associated with a higher prevalence of hypertension, worse 
blood pressure control, and higher rates of sequelae of hypertension, including secondary 
heart disease, renal failure and stroke (57-59). In understanding the reasons for these 
disparities, a key question is whether antihypertensive medication therapy is less effective 
in lowering blood pressure and improving cardiovascular outcomes in lower 
socioeconomic communities. If so, then the implementation of evidence-based therapies 
for hypertension derived from RCTs may be suboptimal in achieving expected outcomes 
in differing socioeconomic populations.  
Antihypertensive medication may be less effective when used in low 
socioeconomic communities for a number of reasons. Living in an under-resourced 
community may be associated with other factors that affect blood pressure, including 
unhealthy lifestyle behaviors related to access to food or facilities, poorer perceived 
health status, differing cultural norms, or practical barriers to eating healthily, exercising, 
and quitting smoking (60-64). Additionally, people living in disadvantaged communities 
may experience changes in blood pressure due to an allostatic load resulting from stress 
associated with unemployment, housing conditions, mental health, financial burdens, 
poor social cohesion, neighborhood safety and violence, and other social ills, further 
contributing to disease progression (65-69). In low income communities, access to high-
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quality primary care is often inadequate, and there may be greater acceptance that 
hypertension is inevitable (70-72). This culture can affect people’s sense of control or 
capacity to lower their risk of cardiovascular events through regular follow-up, 
medication adherence or adoption of lifestyle modifications to halt the progression of 
chronic diseases such as hypertension (73-75).  
Although relationships between these contextual factors and health outcomes 
have been observed and reported in countless observational studies, they are rarely 
measured in RCTs; potentially, some contextual factors may be exerting an unmeasured 
effect on study outcomes. Specifically, in RCTs, while efforts are made to balance 
differences in patient demographic and clinical characteristics, even measurable 
indicators of the socioeconomic environments in which people live, such as area-level 
income are rarely taken into account. To our knowledge, there are no existing studies of 
RCTs of antihypertensive medication therapy which have examined the possible effect of 
socioeconomic context on study participants’ response to antihypertensive medication. 
Thus, despite the provision of standardized hypertensive care and interventions within 
and between study arms in RCTs of antihypertensive medications, unmeasured factors 
related to participants’ socioeconomic environments may contribute to heterogeneity in 
outcomes and limit the generalizability of research findings to some populations (76, 77). 
This is especially problematic because the findings from these RCTs often form the 
cornerstone of treatment guidelines and inform the clinical decisions that practicing 
physicians make every day. Therefore, investigation of the socioeconomic context in an 
RCT may partly explain why the results of RCTs are often not uniformly observed in 
real-world settings (78, 79).  
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The Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial  
To examine the effect of socioeconomic context on response to antihypertensive 
medication in RCTs, we analyzed data from the Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT is the largest randomized, 
double-blinded clinical trial of antihypertensive medical therapy ever, conducted from 
1994 to 2002 with 42,418 original study participants from 623 clinical sites across the 
U.S., Puerto Rico & Virgin Islands, and Canada (10). The study enrolled men and women 
³55 years old with untreated or treated systolic and/or diastolic hypertension and at least 
one additional cardiovascular risk factor (80).  
As the largest ever prospective RCT of antihypertensive treatment, ALLHAT is 
the richest and most reliable data source for secondary analysis. The trial population, 
considered to be demographically diverse, was comprised of nearly 50% women; black 
and Hispanic participants accounted for 36% and 19% of the overall study population, 
respectively (81). The study was considered highly generalizable and sampled across a 
broad socio-geographic distribution, as it enrolled patients from clinical sites throughout 
North America, where blood pressure ascertainment by trained staff was deemed 
consistent and reliable (82, 83). High-quality data was obtained through careful 
adjudication of enrollment criteria, documentation, and confirmation of 99% of 
cardiovascular disease events resulting in death or hospitalization (10). Information was 
collected on potential clinical confounders such as visit-to-visit variability (82). Less than 
1% of drug identities were revealed to either participants or investigators, supporting the 
rigor of blinding (84).  
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Additionally, the findings from ALLHAT have been validated, and extended 
follow-up data are available for most participants using national administrative databases 
(84, 85). The most recent extended follow-up data included fatal outcomes for 98% and 
nonfatal outcomes for 65% of participants (86, 87). Key strengths of the study included 
its design as a randomized double-blind trial, statistical power enabling detection of 
clinically meaningful differences in certain cardiovascular outcomes, a diverse participant 
population, and varied primary care-based clinical settings (private practice, community 
health center, Veterans Affairs Medical Center, academic centers, and HMOs) (10). 
Given that recent guidelines recommend any of the three main classes of antihypertensive 
drugs tested in ALLHAT as first-line medications and the majority of patients in the trial 
needed multiple medications, no future trial will likely provide such undiluted data of the 
effect of first-line antihypertensive agents (85). 
ALLHAT participants were assigned to one of four representative anti-
hypertensive medications: a thiazide diuretic (chlorthalidone), an ACE inhibitor 
(lisinopril), a calcium channel blocker (amlodipine), or an alpha-adrenergic blocker 
(doxazosin) (80). The purpose was to determine whether newer medication classes, such 
as ACE inhibitors and calcium channel blockers – which at the time were costlier than 
the historically-used thiazide diuretics – were as good or better than thiazides in 
preventing adverse cardiovascular outcomes (i.e. fatal coronary heart disease or nonfatal 
myocardial infarction) resulting from hypertension (80). The doxazosin arm was stopped 
early due to inferior treatment effect, but most participants in the other arms were 
followed from 1994 to 2002, with an average of 4.9 years of follow-up (88, 89). The 
main findings, published in 2002, showed that neither amlodipine nor lisinopril were 
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superior to chlorthalidone in improving all-cause mortality or reducing the risk of major 
coronary events (10). Chlorthalidone was superior to amlodipine in preventing heart 
failure but not other kinds of cardiovascular disease, and superior to lisinopril in 
preventing some cardiovascular events, such as stroke, heart failure and coronary 
revascularization.  
A follow-up study indicated that blood pressure control was achieved in a 
majority of patients regardless of randomization, with mildly improved rates of blood 
pressure control in the chlorthalidone group (90). A subsequent comparison of lisinopril 
and amlodipine showed that risk for coronary events was similar, but the risks of stroke, 
gastrointestinal bleeding, and angioedema were higher for lisinopril, possibly due to less 
effective blood pressure control (91). On the basis of cost and overall clinical equivalence 
of thiazides – and even superiority in outcomes such as heart failure and blood pressure 
control – to ACE inhibitors and calcium channel blockers, investigators recommended 
that thiazide diuretics be considered as first-line therapy for treatment of hypertension 
(10, 92). These findings were revisited in the context of subsequent subgroup analyses, 
meta-analyses, and new clinical trials, but the conclusions remained the same (86). 
Meanwhile, a subtrial of ALLHAT was conducted in which participants were randomized 
to pravastatin 40 mg or usual care. In that study, pravastatin did not significantly reduce 
all-cause mortality or coronary heart disease compared with usual care (93). 
The findings from ALLHAT were among the most consequential of any trial of 
hypertension ever conducted, going on to heavily influence recommendations made in the 
JNC 7 and JNC 8 hypertension guidelines described earlier, and even resulting in an 
increase in diuretic prescriptions (9, 12, 94). Numerous follow-up studies and secondary 
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post-hoc analyses of ALLHAT data have been published over the past 15 years, 
examining the effect of various factors acting at the person level, such as race, sex, 
medication adherence, visit adherence, blood pressure control, comorbidities including 
diabetes or chronic kidney disease, medication randomization, medication cost-
effectiveness, statin treatment, and others on study outcomes (29, 82, 83, 85, 87, 95-107). 
However, to date no studies of ALLHAT have considered the effect of socioeconomic 
context or other community-level contextual factors on study outcomes. 
We define socioeconomic context here as the median household income of the 
county in which ALLHAT participants obtained their care (e.g. the ALLHAT clinical 
sites). Postulating that socioeconomic context, a proxy for unmeasured contextual factors 
such as social stressors and lifestyle behaviors, may impact overall treatment response in 
the trial, we compared baseline and clinical characteristics, visit and medication 
adherence, blood pressure control, and cardiovascular outcomes among ALLHAT 
participants of varying socioeconomic context. Understanding the relationship between 
socioeconomic context and outcomes can guide the generalizability of RCT findings, 
promote the assessment of participants’ socioeconomic context in clinical trials, and 
ultimately, inform broader strategies for combating hypertension in populations living in 
low socioeconomic environments. 
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Statement of purpose 
 
Specific Aim: In this study, I aim to assess the relationship between the socioeconomic 
context in which participants obtained clinical care with response to antihypertensive 
medication, as measured by blood pressure control and key adverse cardiovascular 
outcomes in ALLHAT, the largest-ever RCT of hypertension.  
 
Hypothesis: ALLHAT participants obtaining care in lower income areas will have a 
lower likelihood of achieving blood pressure control (defined as a blood pressure less 
than 140/90 mmHg) and a higher risk of experiencing the main primary and secondary 
adverse cardiovascular outcomes defined in the original trial.  
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Methods 
 
Contributions 
I, the student, was the intellectual driver of this research. I was responsible for 
conducting the literature review, creating the research proposal, formulating a plan for 
data acquisition, designing an analytic plan, and working closely with our statistician to 
analyze and interpret our data. As the lead author on this project, I was also responsible 
for creating all posters and presentations, and writing the resulting manuscript.   
 
Overview  
We conducted a secondary analysis of ALLHAT to examine the effect of 
socioeconomic context on study outcomes. To measure socioeconomic context, we used 
the income level of the county in which the clinical site was located, assuming 
participants lived in nearby communities and therefore were exposed to a similar 
socioeconomic context as the clinical site. We then assessed the distribution of 
participants’ income status compared with the national mean in 2000 (when the trial was 
underway), and compared baseline characteristics and outcomes of participants in 
quintile 1 (Q1, lowest socioeconomic status) with participants in quintile 5 (Q5, highest 
socioeconomic status). To better understand whether demographic factors such as race 
and region of care, previously associated with hypertension outcomes but also associated 
with socioeconomic status, confounded any differences observed, we also assessed 
differences by income quintile among two subgroups, black participants and clinical sites 
in the South.  
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ALLHAT study design and organization 
Details of the rationale, study design, and main findings for ALLHAT have been 
explained above and are extensively described in the literature (10, 80, 88). ALLHAT 
originally enrolled 42,418 men and women ³55 years old with untreated systolic (defined 
as 140 £ 180 mmHg) and/or diastolic (90 £ 110 mmHg) hypertension present on ³2 
visits, or treated hypertension (£160/110 mmHg on 1-2 antihypertensive medications at 
visit 1 [where participants were assessed for study eligibility] and £180/110 mmHg at 
visit 2 [where participants were randomized after stepdown from any pre-study 
antihypertensive drugs]) (80). Eligible study participants also had at least one additional 
cardiovascular risk factor (80). These risk factors included: history of atherosclerotic 
cardiovascular disease (CVD); history of myocardial infarction or stroke; history of 
coronary revascularization; other atherosclerotic CVD; history of ST depression or T-
wave inversion on electrocardiogram (ECG); type 2 diabetes; a high-density lipoprotein 
C (HDL-C) of <35 mg/dL at least twice in the five years prior to the trial; left ventricular 
hypertrophy (LVH) by ECG in the 2 years prior to the trial; LVH by echocardiogram in 
the 2 years prior to the trial; history of coronary heart disease (CHD) at baseline; body 
mass index (BMI); aspirin use at the start of the trial; cigarette smoking; and estrogen 
supplementation at the time of the trial. 
The study was conducted from 1994 to 2002, with a mean of 4.9 years of follow-
up (108). Visit frequency included follow-up at 1 month; 3, 6, 9, and 12 months; and 
every 4 months thereafter (more often as needed), which was considered usual for 
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hypertension care (10, 85). Patients were assigned to one of four representative anti-
hypertensive medications – a thiazide diuretic (chlorthalidone), an ACE inhibitor 
(lisinopril), a calcium channel blocker (amlodipine), or an alpha-adrenergic blocker 
(doxazosin, stopped early due to inferior treatment effect) – with discouragement of 
mixing therapies (89). Because blood response was one of the main outcomes and most 
participants continued to have uncontrolled blood pressure (defined as >140/90 mmHg) 
despite titration of the assigned study drug, second-line medications (atenolol, clonidine, 
or reserpine) were added as needed in a step-wise fashion (10). Study outcomes were 
collected through a variety of means: at follow-up visits, from clinical investigator 
reports, or other documentation such as a death certificate or a hospital discharge 
summary; 99% of cardiovascular events were documented across all 3 treatment groups 
(10). Protocols outlining follow-up visits, treatment procedures, and endpoint 
ascertainment have been described elsewhere in the biomedical literature (80, 88). 
Participating sites acquired institutional review board (IRB) approval and obtained 
written informed consent from all participants (10). 
 The primary study outcome was coronary heart disease [CHD] (fatal CHD and 
nonfatal myocardial infarction [MI] combined). Four major pre-specified secondary 
outcomes were also defined: (1) all-cause mortality, (2) stroke, combined CHD (CHD, 
coronary revascularization, or hospitalized angina), and (4) combined cardiovascular 
disease [CVD] (combined CHD, stroke, other treated angina, heart failure [HF], or 
peripheral arterial disease). The original trial investigators also assessed subcomponents 
of these major outcomes as well as other pre-specified secondary outcomes, including 
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cancer, left ventricular hypertrophy by ECG, hospitalization for GI bleed, end-stage renal 
disease (ESRD), quality of life, and health care costs (10). 
 
Income data 
ALLHAT data was obtained from the NHLBI’s Biologic Specimen and Data 
Repositories Information Coordinating Center (BioLINCC). We did not have access to 
the ZIP codes or counties in which participants resided, so we instead used enrollment 
site ZIP codes, obtained from the original ALLHAT investigators, and mapped these to 
one or more site-specific counties. We selected county-level median household income as 
a proxy for the socioeconomic context in which patients received their care, derived from 
the 2000 U.S. Census, the closest year to the period in which the study was conducted. 
County-level incomes were adjusted for cost of living in each state in the year 2000. If 
the ZIP code mapped to more than one county, we calculated the population-weighted 
average median income across those counties. County-level incomes were assigned to 
study participants at that site. Based on the national distribution of county-level 
household median income, individuals were stratified into income quintiles. 
 
Exclusion criteria 
We excluded participants enrolled in sites outside of the continental U.S. 
(n=5,277), due to potential confounders when comparing socioeconomic context of those 
sites with sites in the continental U.S., participants in sites lacking income data (n=304) 
and participants randomized to doxazosin (n=9,061 participants). After these exclusions, 
a total of 27,826 participants were included in this study (see Figure 1). 
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Figure 1. Flow chart of study exclusion criteria 
 
Outcomes 
We assessed blood pressure control and major adverse cardiovascular events as 
pre-specified in ALLHAT. Blood pressure control was defined as the proportion 
achieving the ALLHAT treatment goal of 140/90 in years 1-6, regardless of age (80). The 
primary and four key secondary cardiovascular outcomes, defined in ALLHAT, were: (1) 
CHD, (2) all-cause mortality, stroke, (4) combined CHD, and (5) combined CVD (each 
defined above). We also evaluated the following individual components of these 
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outcomes: heart failure, hospitalized/fatal heart failure, angina, coronary 
revascularization, peripheral arterial disease, and ESRD. 
 
Statistical Analysis 
We compared baseline characteristics, treatment, visit and medication adherence, 
unadjusted blood pressure response and unadjusted cardiovascular outcomes of the study 
population by income quintile. As captured in the original trial, we defined visit 
adherence as the number of attended visits divided by the protocol-determined number of 
expected visits in the six-year duration of the trial. Adequate visit adherence was defined 
as attending at least 80% of expected visits. We defined adequate medication adherence 
as taking at least 80% of study medications at all visits, per participants’ self-report. We 
then tested the association between socioeconomic context with blood pressure control 
and cardiovascular outcomes in the lowest and highest income quintiles, with the highest 
income quintile (Q5) serving as the reference group, using logistic regression and Cox 
proportional hazards regression analysis, respectively. In this model, we adjusted for 
treatment group, age, sex, qualifying ALLHAT risk factors (see ALLHAT study design 
and organization, above), and baseline systolic blood pressure (SBP) and diastolic blood 
pressure (DBP), using imputation if study participants had missing values for certain risk 
factors.  
Next, we performed subgroup analyses of blood pressure response and 
cardiovascular outcomes across socioeconomic strata (1) among black participants, and 
(2) among participants in the South. Last, to assess whether fidelity to the protocol 
explained any of the differences between groups, we performed an exploratory analysis 
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adjusting for visit adherence in addition to baseline and clinical characteristics. Though 
visit adherence is potentially endogenous with the outcome – that is, patients with a 
clinical outcome prior to the six-year endpoint may be more likely to adhere to 
subsequent visits – we included it in the final model to assess whether it attenuated the 
main differences. There was insufficient data of participants’ medication adherence to 
include it in the model. This study was approved by the Yale Human Investigations 
Committee. 
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Results 
 
Geographic distribution of clinical sites 
The 27,826 participants included in this study obtained care in clinical sites 
representing 372 U.S. counties, depicted in Figure 2. Nearly all (32/35, 91%) of the 
lowest-income counties (Q1) were in the South, whereas the highest-income counties 
(Q5) were more evenly distributed across geographic regions.  
 
Figure 2. Geographic distribution and socioeconomic (income) stratification of U.S. 
counties with clinical sites participating in ALLHATA 
 
 
 
 
 
 
 
 
 
 
 
 
a Image created using mapchart.net. 
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Baseline characteristics 
Baseline demographic and clinical characteristics, qualifying risk factors, and 
treatment group randomization across income strata in ALLHAT are shown in Table 1. 
Participants enrolled in the lowest income sites (Q1, bottom income quintile) comprised 
7.8% of the study population, while those enrolled in the highest income sites (Q5, top 
income quintile) comprised 37.6% of the study population. Participants in Q1 tended to 
be younger, female, black or Hispanic, and had attained lower levels of education than 
participants in Q5. The county-level cost-of-living-adjusted median household income 
was 2.8 times higher in Q5, as compared to Q1. Participants from the South made up 
more than 98% of people in Q1 but only 18.6% of people in Q5. Participants across 
economic strata entered the trial with similar clinical characteristics, including similar 
baseline blood pressures, GFR, potassium, fasting glucose, and numbers of 
antihypertensive medications prior to the trial. Compared to Q5, fewer participants in Q1 
had a history of atherosclerotic cardiovascular disease, had ever smoked, or were on 
aspirin. A greater proportion of Q1 participants enrolled in the lipid trial portion of 
ALLHAT, as well. Participants across strata were equally likely to have type II diabetes. 
Additionally, there were similar numbers of participants in each treatment arm across 
socioeconomic strata, consistent with randomization. 
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Table 1. Baseline characteristics of study population across socioeconomic strata 
 County income level 
Characteristic Q1A 
N (%) or 
Mean (SD) 
Q2 
N (%) or 
Mean (SD) 
Q3 
N (%) or 
Mean (SD) 
Q4 
N (%) or 
Mean (SD) 
Q5 
N (%) or 
Mean (SD) 
Demographics 
Total participants 2169 3562 4916 6721 10458 
Age 66.1 (8.4) 66.4 (7.4) 67.1 (7.7) 67.1 (7.4) 67.0 (7.5) 
Female 1285 (59.2) 1645 (46.2) 2242 (45.6) 2899 (43.1) 4570 (43.7) 
Race      
 White 242 (11.2) 1353 (38.0) 3208 (65.3) 4121 (61.3) 6830 (65.3) 
 Black 1524 (70.3) 2189 (61.5) 1477 (30.0) 2432 (36.2) 2910 (27.8) 
 American Indian 1 (0.1) 6 (0.2) 20 (0.4) 9 (0.1) 31 (0.3) 
 Asian/Pacific Islander 1 (0.1) 2 (0.1) 15 (0.3) 26 (0.4) 322 (3.1) 
 Other 401 (18.5) 12 (0.3) 196 (4.0) 133 (2.0) 365 (3.5) 
Hispanic 433 (20.0) 54 (1.5) 332 (6.8) 276 (4.1) 592 (5.7) 
Education      
 High School or Less 1855 (85.5) 2807 (78.8) 3383 (68.8) 4221 (62.8) 6090 (58.2) 
 College 163 (7.5) 499 (14.0) 978 (19.9) 1630 (24.3) 2924 (28.0) 
 Post-graduate 46 (2.1) 111 (3.1) 209 (4.3) 373 (5.6) 774 (7.4) 
County characteristics      
COLA median income ($ k) 21.8 (2.4) 29.2 (1.1) 33.0 (1.3) 38.2 (1.6) 49.6 (8.7) 
Number of counties 35 45 62 75 155 
Number of participants by geographic region 
 East 2 (0.1) 12 (0.3) 748 (15.2) 1687 (25.1) 2545 (24.3) 
 South 2134 (98.4) 3216 (90.3) 3399 (69.1) 2919 (43.4) 1941 (18.6) 
 Midwest 2 (0.1) 322 (9.0) 510 (10.4) 1892 (28.2) 3299 (31.6) 
 West 31 (1.4) 12 (0.3) 259 (5.3) 223 (3.3) 2673 (25.6) 
Baseline clinical characteristics 
Systolic blood pressure (SBP) 145.0 (16.8) 145.3 (15.8) 145.7 (15.9) 147.5 (15.6) 145.7 (15.5) 
Diastolic blood pressure (DBP) 83.7 (10.7) 82.9 (10.0) 82.3 (10.2) 84.1 (9.9) 83.7 (10.0) 
GFRB 80.4 (21.8) 79.7 (21.3) 76.5 (19.2) 77.0 (19.6) 76.8 (18.9) 
CreatinineB 1.0 (0.3) 1.1 (0.3) 1.0 (0.3) 1.0 (0.3) 1.0 (0.3) 
PotassiumB 4.3 (0.7) 4.3 (0.7) 4.3 (0.7) 4.3 (0.7) 4.4 (0.6) 
Fasting glucoseB 127.2 (61.7) 128.4 (63.0) 121.5 (55.3) 123.0 (58.7) 120.9 (53.1) 
Receiving anti-hypertensive treatment 
 On 1-2 meds >= 2 months 1831 (84.4) 3086 (86.6) 4270 (86.9) 5809 (86.4) 9080 (86.8) 
 On meds < 2 months 58 (2.7) 126 (3.5) 137 (2.8) 273 (4.1) 365 (3.5) 
 Untreated at baseline 280 (12.9) 350 (9.8) 509 (10.4) 639 (9.5) 1012 (9.7) 
Qualifying risk factors for ALLHAT 
History of atherosclerotic CVDC 904 (41.7) 1706 (47.9) 2556 (52.0) 3786 (56.3) 5721 (54.7) 
History of MI or stroke 309 (14.3) 876 (24.6) 1202 (24.5) 1731 (25.8) 2585 (24.7) 
History of coronary revascularization 102 (4.7) 391 (11.0) 780 (15.9) 986 (14.7) 1693 (16.2) 
Other atherosclerotic CVD 398 (18.4) 563 (15.8) 1117 (22.7) 1792 (26.7) 2720 (26.0) 
History of ST dep/T-wave inv 286 (13.2) 448 (12.6) 472 (9.6) 768 (11.4) 1003 (9.6) 
Type II diabetes 770 (35.5) 1450 (40.7) 1773 (36.1) 2333 (34.7) 3624 (34.7) 
HDL-C <35 mg/dL twice in past 5 years 72 (3.3) 270 (7.6) 606 (12.3) 913 (13.6) 1491 (14.3) 
LVH by ECG in past 2 years 640 (29.5) 674 (18.9) 692 (14.1) 977 (14.5) 1547 (14.8) 
LVH by echocardiogram in past 2 years 86 (4.0) 117 (3.3) 231 (4.7) 231 (3.4) 568 (5.4) 
History of CHD at baseline 14 (0.7) 41 (1.2) 71 (1.4) 81 (1.2) 132 (1.3) 
BMI 30.4 (6.4) 29.9 (6.2) 29.5 (5.8) 30.0 (6.0) 29.7 (6.1) 
Current aspirin use 568 (26.2) 1186 (33.3) 1916 (39.0) 2705 (40.3) 4089 (39.1) 
Current estrogen supplementationD 146 (6.7) 240 (6.7) 471 (9.6) 518 (7.7) 1059 (10.1) 
Lipid trial participants 720 (33.2) 922 (25.9) 1264 (25.7) 1362 (20.3) 2303 (22.0) 
Cigarette Smoker      
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 Current 485 (22.4) 907 (25.5) 1114 (22.7) 1531 (22.8) 2173 (20.8) 
 Past 678 (31.3) 1338 (37.6) 2046 (41.6) 2963 (44.1) 4616 (44.1) 
 Never 1006 (46.4) 1317 (37.0) 1755 (35.7) 2227 (33.1) 3668 (35.1) 
Treatment Group (antihypertensive randomization group) 
Chlorthalidone 994 (45.8) 1625 (45.6) 2254 (45.9) 3077 (45.8) 4774 (45.7) 
Amlodipine 587 (27.1) 967 (27.2) 1333 (27.1) 1807 (26.9) 2851 (27.3) 
Lisinopril 588 (27.1) 970 (27.2) 1329 (27.0) 1837 (27.3) 2833 (27.1) 
Abbreviations: N, number of participants; SD, standard deviation; COLA, cost-of-living-
adjusted median income; GFR, glomerular filtration rate; CVD, cardiovascular disease; 
MI, myocardial infarction; dep, depression; inv, inversion; HDL, high-density 
lipoprotein; LVH, left ventricular hypertrophy; ECG, electrocardiogram; CHD, coronary 
heart disease; BMI, body mass index. 
 
A Q1 represents study participants who obtained care at clinical sites located in counties 
that fall into the lowest income quintile nationally. Q5 represents the highest income 
quintile. 
B Numbers may not add to total because of missing data.  
C History of atherosclerotic CVD contains the following categories: history of MI or 
stroke, history of coronary revascularization, history of major ST segment depression or 
T-wave inversion on any ECG in the past 2 years, and other atherosclerotic CVD. 
D Applies to female participants only. 
 
 
Visit and medication adherence  
Table 2 shows differences in visit and medication adherence for participants 
across income strata. Participants in Q1 had lower visit adherence (29.7%) than those in 
Q5 (40.8%; P<0.001). Adequate medication adherence was also lower among 
participants in Q1 (36.3%) compared with participants in Q5 (55.6%; P<0.001). Overall, 
both visit and medication adherence were similar for participants in Q2-Q5, though 
participants in Q2 had the highest adequate visit adherence (44.6%) and medication 
adherence (61.1%). Importantly, data on medication adherence was missing in 21.8-
38.0% of participants in each income quintile, while visit adherence was only missing in 
0.8-1.5% of participants in each income quintile. 
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Table 2. Visit and medication adherence of study population across socioeconomic strata 
 County income level 
Characteristic Q1A 
N (%) 
Q2 
N (%) 
Q3 
N (%) 
Q4 
N (%) 
Q5 
N (%) 
Total participants 2169 3562 4916 6721 10458 
Visit adherenceB      
 < 80% 1498 (69.1) 1946 (54.6) 2812 (57.2) 4099 (61.0) 6085 (58.2) 
 ³ 80% 644 (29.7) 1588 (44.6) 2044 (41.6) 2524 (37.6) 4264 (40.8) 
 Missing 27 (1.2) 28 (0.8) 60 (1.2) 98 (1.5) 109 (1.0) 
Medication adherenceC      
 Ever < 80% 557 (25.7) 610 (17.1) 930 (18.9) 1300 (19.3) 2289 (21.9) 
 Always ³ 80% 788 (36.3) 2176 (61.1) 2766 (56.3) 3668 (54.6) 5810 (55.6) 
 Missing 824 (38.0) 776 (21.8) 1220 (24.8) 1753 (26.1) 2359 (22.6) 
Abbreviations: Q1, lowest income quintile, Q5, highest income quintile; N, number of 
participants. 
 
A Q1 represents study participants who obtained care at clinical sites located in counties 
that fall into the lowest income quintile nationally. Q5 represents the highest income 
quintile. 
B Visit adherence was defined as the number of visits at six years divided by the number 
of expected visits. Adequate visit adherence was defined as attending ³80% of expected 
visits.  
C Adequate medication adherence was defined as always taking ³80% of medications 
(self-reported by participants). 
 
 
Blood pressure control 
To assess blood pressure response across socioeconomic strata, we first compared 
absolute and relative changes in blood pressure between participants in the two income 
groups. Participants in Q1 on average experienced a smaller decrease in SBP (-2.6 
mmHg) and DBP (-5.8 mmHg) than those in Q5 (SBP, -12.1 mmHg; DBP, -9.9 mmHg) 
during the trial (P<0.001). By the end of the trial, Q1 participants had an average blood 
pressure of 140/78; meanwhile, participants in Q5 had an average blood pressure of 
133/74 (Tables 3A-B). We then calculated the unadjusted rates of participants achieving 
blood pressure control (<140/90 mmHg) across socioeconomic groups and treatment 
arms (Tables 4A-D). Blood pressure control was substantially lower in Q1 than in the 
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remaining income quintiles (Q2-5). Overall, by year 6 of the trial, 50.0% of participants 
in Q1 had attained blood pressure control, as compared with 70.2% of participants in Q5. 
Notably, the share of Q1 participants who attained blood pressure control plateaued at 
50% after year 3 or 4; on the other hand, for Q5 participants, this percentage increased 
year after year. These results were similar for each of the treatment arms. Finally, we 
compared the likelihood of achieving blood pressure control in Q1 and Q5 participants, 
adjusting for baseline demographics, clinical characteristics, risk factors, and treatment 
arm, with Q5 serving as the reference group (Table 5). Participants in Q1 were 
significantly less likely to achieve blood pressure control than those in Q5 after 1 year in 
the trial (44.8% vs 57.3%; OR, 0.63; 95% CI, 0.56-0.70), a difference which persisted 
each year of the trial and even increased after 6 years (50.0% vs 69.3%; OR, 0.48; 95% 
CI, 0.37-0.63).  
 
Table 3A. Mean blood pressure at years 1-6, stratified by income level 
 County Income Level 
Outcome Q1 
Mean (SD) 
Q2 
Mean (SD) 
Q3 
Mean (SD) 
Q4 
Mean (SD) 
Q5 
Mean (SD) 
Systolic blood pressure 
	 Year	1	 140.5	(18.6)	 139.5	(16.9)	 138.4	(17.3)	 138.9	(16.2)	 137.7	(16.0)	
	 Year	2	 140.8	(19.1)	 138.2	(16.3)	 137.0	(17.2)	 137.6	(16.2)	 136.7	(15.9)	
	 Year	3	 139.8	(18.4)	 136.5	(16.6)	 135.7	(16.6)	 136.2	(16.2)	 135.4	(15.5)	
	 Year	4	 138.5	(18.4)	 136.3	(17.0)	 134.9	(16.5)	 135.1	(16.3)	 134.1	(15.3)	
	 Year	5	 138.3	(19.0)	 135.9	(16.7)	 134.7	(16.7)	 134.4	(15.6)	 134.0	(14.9)	
	 Year	6	 139.9	(21.3)	 135.2	(17.6)	 134.6	(16.1)	 133.4	(15.9)	 133.2	(15.9)	
Diastolic	blood	pressure	
	 Year	1	 80.8	(11.1)	 79.3	(9.9)	 78.1	(10.1)	 79.6	(9.8)	 79.2	(9.8)	
	 Year	2	 80.0	(10.8)	 78.4	(9.9)	 77.3	(10.5)	 78.2	(9.9)	 78.1	(9.7)	
	 Year	3	 78.8	(10.5)	 77.1	(10.0)	 76.3	(10.3)	 76.7	(10.3)	 76.8	(9.6)	
	 Year	4	 78.7	(10.9)	 76.6	(9.9)	 75.5	(10.2)	 75.9	(10.0)	 76.0	(9.8)	
	 Year	5	 78.5	(11.1)	 75.6	(10.0)	 74.4	(10.6)	 74.3	(10.0)	 75.1	(9.8)	
	 Year	6	 78.2	(11.5)	 73.8	(10.6)	 73.6	(10.2)	 73.4	(9.8)	 74.0	(10.0)	
Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; SD, standard 
deviation. 
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Table 3B. Mean change in blood pressure from baseline at years 1-6, stratified by income 
level 
 County Income Level 
Outcome Q1 
Mean (SD) 
Q2 
Mean (SD) 
Q3 
Mean (SD) 
Q4 
Mean (SD) 
Q5 
Mean (SD) 
Change in systolic blood pressure compared with baseline 
	 Year	1	 -4.0	(21.5)	 -5.7	(19.2)	 -7.1	(20.1)	 -8.4	(19.3)	 -7.8	(19.0)	
	 Year	2	 -3.2	(22.5)	 -6.9	(19.6)	 -8.5	(21.1)	 -9.6	(19.2)	 -8.7	(19.1)	
	 Year	3	 -4.3	(21.8)	 -8.5	(20.5)	 -9.8	(20.4)	 -11.0	(20.0)	 -9.9	(19.1)	
	 Year	4	 -5.3	(21.7)	 -8.5	(20.9)	 -10.5	(20.6)	 -11.9	(20.0)	 -11.1	(19.3)	
	 Year	5	 -4.6	(21.8)	 -9.2	(20.7)	 -11.1	(21.2)	 -12.4	(19.9)	 -11.3	(19.5)	
	 Year	6	 -2.6	(24.5)	 -9.8	(21.6)	 -10.9	(20.5)	 -13.1	(20.1)	 -12.1	(20.3)	
Change	in	diastolic	blood	pressure	compared	with	baseline	
	 Year	1	 -2.7	(12.1)	 -3.5	(10.6)	 -4.2	(11.3)	 -4.4	(10.9)	 -4.4	(10.7)	
	 Year	2	 -3.4	(12.2)	 -4.3	(11.2)	 -5.0	(11.8)	 -5.9	(11.1)	 -5.5	(11.0)	
	 Year	3	 -4.7	(12.1)	 -5.5	(11.8)	 -6.0	(12.1)	 -7.4	(11.6)	 -6.8	(11.0)	
	 Year	4	 -4.9	(12.3)	 -6.0	(11.7)	 -6.7	(12.2)	 -8.1	(11.4)	 -7.5	(11.3)	
	 Year	5	 -5.2	(12.3)	 -7.1	(11.6)	 -7.8	(12.8)	 -9.2	(11.3)	 -8.6	(11.4)	
	 Year	6	 -5.8	(12.8)	 -8.7	(12.0)	 -8.4	(12.5)	 -10.4	(11.4)	 -9.9	(11.6)	
Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; SD, standard 
deviation. 
 
 
 
Table 4A. Blood pressure controlA for all treatment groups combined, stratified by 
income level 
 County Income Level 
Outcome Q1 
N (%) 
Q2 
N (%) 
Q3 
N (%) 
Q4 
N (%) 
Q5 
N (%) 
Year 1 786 (44.8) 1625 (51.2) 2299 (54.9) 3037 (53.2) 5284 (57.3) 
Year 2 695 (45.2) 1578 (54.7) 2170 (57.6) 2916 (57.1) 5073 (59.6) 
Year 3 657 (48.1) 1580 (59.8) 2099 (61.0) 2867 (61.3) 4950 (63.6) 
Year 4 561 (50.2) 1489 (62.0) 1950 (63.4) 2734 (64.8) 4715 (67.1) 
Year 5 344 (51.2) 1055 (63.9) 1224 (65.0) 1635 (67.5) 2874 (68.0) 
Year 6 140 (50.0) 575 (64.3) 677 (64.7) 956 (71.6) 1499 (69.3) 
Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; N, number of 
participants. 
 
A Blood pressure control is represented as the unadjusted number or percentage of 
participants achieving blood pressure control (<140/90 mmHg) in years 1-6 of ALLHAT, 
for each income level. 
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Table 4B. Blood pressure controlA for chlorthalidone treatment arm 
 County Income Level 
Outcome Q1 
N (%) 
Q2 
N (%) 
Q3 
N (%) 
Q4 
N (%) 
Q5 
N (%) 
Year 1 394 (48.9) 787 (53.5) 1103 (57.1) 1490 (56.7) 2522 (59.7) 
Year 2 356 (50.7) 783 (57.9) 1049 (60.0) 1432 (60.2) 2437 (62.1) 
Year 3 325 (51.8) 780 (63.2) 997 (62.7) 1360 (62.8) 2317 (64.6) 
Year 4 274 (53.4) 736 (65.8) 911 (63.5) 1299 (67.0) 2196 (67.9) 
Year 5 153 (50.2) 510 (67.3) 577 (65.9) 779 (69.8) 1392 (71.1) 
Year 6 63 (50.0) 278(69.7) 310 (64.0) 454 (72.2) 694 (70.2) 
Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; N, number of 
participants. 
 
A Blood pressure control is represented as the unadjusted number or percentage of 
participants achieving blood pressure control (<140/90 mmHg) in years 1-6 of ALLHAT, 
for each income level. 
 
 
Table 4C. Blood pressure controlA for amlodipine treatment arm 
 County Income Level 
Outcome Q1 
N (%) 
Q2 
N (%) 
Q3 
N (%) 
Q4 
N (%) 
Q5 
N (%) 
Year 1 197 (41.8) 455 (52.7) 610 (53.6) 799 (52.5) 1472 (58.3) 
Year 2 171 (41.0) 427 (54.9) 580 (56.3) 788 (57.6) 1368 (58.7) 
Year 3 179 (47.7) 437 (60.0) 574 (60.5) 782 (61.8) 1411 (65.7) 
Year 4 148 (47.4) 395 (59.8) 553 (64.8) 740 (64.2) 1336 (68.4) 
Year 5 100 (54.1) 308 (65.1) 349 (65.1) 444 (67.1) 800 (68.3) 
Year 6 37 (46.3) 162 (60.9) 203 (67.4) 254 (71.3) 405 (68.3) 
Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; BP, N, number 
of participants. 
 
A Blood pressure control is represented as the unadjusted number or percentage of 
participants achieving blood pressure control (<140/90 mmHg) in years 1-6 of ALLHAT, 
for each income level. 
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Table 4D. Blood pressure controlA for lisinopril treatment arm 
 County Income Level 
Outcome Q1 
N (%) 
Q2 
N (%) 
Q3 
N (%) 
Q4 
N (%) 
Q5 
N (%) 
Year 1 195 (40.8) 383 (45.7) 586 (52.5) 748 (48.1) 1290 (52.3) 
Year 2 168 (40.2) 368 (48.6) 541 (54.8) 696 (51.2) 1268 (56.1) 
Year 3 153 (42.1) 363 (53.5) 528 (58.5) 725 (58.4) 1222 (59.7) 
Year 4 139 (47.4) 358 (57.5) 486 (61.5) 695 (61.6) 1183 (64.3) 
Year 5 91 (50.0) 237 (56.4) 298 (63.1) 412 (63.8) 682 (62.2) 
Year 6 40 (54.1) 135 (59.0) 164 (62.8) 248 (70.7) 400 (68.8) 
Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; N, number of 
participants. 
 
A Blood pressure control is represented as the unadjusted number or percentage of 
participants achieving blood pressure control (<140/90 mmHg) in years 1-6 of ALLHAT, 
for each income level. 
 
 
 
Table 5. Association between income and blood pressure control across income strata 
Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; OR, odds ratio; 
BP, blood pressure; CI, confidence interval. 
 
A Risk-adjusted OR represents odds of achieving blood pressure control (< 140/90 
mmHg), with the highest income quintile, Q5, serving as the reference group. Model 
adjusts for treatment group, age, sex, baseline SBP and DBP, and qualifying risk factors 
for ALLHAT (BMIB, history of MI or stroke, history of coronary revascularization, 
history of CHD at baseline, other ASCVD, participation in lipid-lowering trial, type II 
diabetes, history of major ST depression or T-wave inversionB, aspirin use, HDL-C < 35 
mg/dL, LVH by ECG, LVH by echocardiogramB, cigarette smokingB, and estrogen 
supplementationB).  
B A minority of study participants have missing values for these risk factors. The missing 
values for these participants were imputed.  
 
Among black participants, we observed similar trends in attainment of target 
blood pressure between economic strata (Table 6A); black participants receiving care in 
 County Income Level Low Income Effect 
Outcome Q1 
% with BP <140/90 mmHg 
Q5 
% with BP <140/90 mmHg 
Risk-Adjusted ORA 
OR (95% CI) 
Year 1 44.8 57.3 0.63 (0.56-0.70) 
Year 2 45.2 59.6 0.58 (0.52-0.66) 
Year 3 48.1 63.6 0.55 (0.49-0.62) 
Year 4 50.2 67.1 0.53 (0.46-0.60) 
Year 5 51.2 68.0 0.51 (0.43-0.61) 
Year 6 50.0 69.3 0.48 (0.37-0.63) 
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Q1 were less likely than black participants receiving care in Q5 to achieve blood pressure 
control after 1 year (OR, 0.70; 95% CI, 0.61-0.81) and each year through year 6 (OR, 
0.53; 95% CI, 0.38-0.74). Similarly, among clinical sites located in the South, 
participants in Q1 were less likely to achieve blood pressure control each year including 
year 1 (OR, 0.66; 95% CI, 0.56-0.77) and year 6 (OR, 0.51; 95% CI, 0.34-0.76) 
compared with participants in Q5 (Table 6B). In the exploratory analyses, which 
included visit adherence in the model, results were unchanged (Table 7). Participants in 
Q1 were less likely to achieve blood pressure control, even when visit adherence was 
taken into account, at year 1 (OR, 0.63; 95% CI, 0.57-0.70) and year 6 (OR, 0.48; 95% 
CI, 0.36-0.62). 
 
Table 6A. Association between income and blood pressure control among black 
ALLHAT participants across socioeconomic strata 
Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; OR, odds ratio; 
BP, blood pressure; CI, confidence interval. 
 
A Risk-adjusted OR represents odds of achieving blood pressure control (< 140/90 
mmHg), with the highest income quintile, Q5, serving as the reference group. Model 
adjusts for treatment group, age, sex, baseline SBP and DBP, and qualifying risk factors 
for ALLHAT (BMIB, history of MI or stroke, history of coronary revascularization, 
history of CHD at baseline, other ASCVD, participation in lipid-lowering trial, type II 
diabetes, history of major ST depression or T-wave inversionB, aspirin use, HDL-C < 35 
mg/dL, LVH by ECG, LVH by echocardiogramB, cigarette smokingB, and estrogen 
supplementationB).  
B A minority of study participants have missing values for these risk factors. The missing 
values for these participants were imputed.  
 
 
 County Income Level Low Income Effect 
Outcome Q1 
% with BP <140/90 mmHg 
Q5 
% with BP <140/90 mmHg 
Risk-Adjusted ORA 
OR (95% CI) 
Year 1 43.5 51.7 0.70 (0.61-0.81) 
Year 2 44.8 52.8 0.73 (0.62-0.85) 
Year 3 46.4 57.6 0.65 (0.55-0.76) 
Year 4 50.8 61.3 0.69 (0.58-0.82) 
Year 5 49.1 63.7 0.55 (0.44-0.69) 
Year 6 46.5 63.2 0.53 (0.38-0.74) 
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Table 6B. Association between income and blood pressure control among ALLHAT 
participants living in the South across socioeconomic strata 
 
Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; OR, odds ratio; 
BP, blood pressure; CI, confidence interval. 
 
A Risk-adjusted OR represents odds of achieving blood pressure control (< 140/90 
mmHg), with the highest income quintile, Q5, serving as the reference group. Model 
adjusts for treatment group, age, sex, baseline SBP and DBP, and qualifying risk factors 
for ALLHAT (BMIB, history of MI or stroke, history of coronary revascularization, 
history of CHD at baseline, other ASCVD, participation in lipid-lowering trial, type II 
diabetes, history of major ST depression or T-wave inversionB, aspirin use, HDL-C < 35 
mg/dL, LVH by ECG, LVH by echocardiogramB, cigarette smokingB, and estrogen 
supplementationB).  
B A minority of study participants have missing values for these risk factors. The missing 
values for these participants were imputed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 County Income Level Low Income Effect 
Outcome Q1 
% with BP <140/90 mmHg 
Q5 
% with BP <140/90 mmHg 
Risk-Adjusted ORA 
OR (95% CI) 
Year 1 44.5 57.6 0.66 (0.56-0.77) 
Year 2 44.9 57.0 0.72 (0.61-0.85) 
Year 3 47.5 60.4 0.63 (0.53-0.75) 
Year 4 49.9 63.7 0.61 (0.51-0.74) 
Year 5 50.9 62.3 0.67 (0.52-0.86) 
Year 6 50.0 69.7 0.51 (0.34-0.76) 
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Table 7. Association between income and blood pressure control across socioeconomic 
strata, adjusted for visit adherence 
Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; OR, odds ratio; 
BP, blood pressure; CI, confidence interval. 
 
A Risk-adjusted OR represents odds of achieving blood pressure control (< 140/90 
mmHg), with the highest income quintile, Q5, serving as the reference group. Model 
adjusts for treatment group, age, sex, baseline SBP and DBP, qualifying risk factors for 
ALLHAT (BMIB, history of MI or stroke, history of coronary revascularization, history 
of CHD at baseline, other ASCVD, participation in lipid-lowering trial, type II diabetes, 
history of major ST depression or T-wave inversionB, aspirin use, HDL-C < 35 mg/dL, 
LVH by ECG, LVH by echocardiogramB, cigarette smokingB, and estrogen 
supplementationB), and six year visit adherenceB.  
B A minority of study participants have missing values for these risk factors. The missing 
values for these participants were imputed. 
 
 
Cardiovascular outcomes 
We then compared rates of pre-specified time-to-event cardiovascular outcomes 
that occurred throughout the trial, across socioeconomic strata and treatment arms 
(Tables 8A-D). The rate of the primary outcome, CHD, was lower in Q1 than in Q5 
overall (6.9% vs 9.6%); this was consistent across the treatment groups. Fewer 
participants in Q1 (compared with Q5) received coronary revascularization (4.2% vs 
8.7%) or were hospitalized or treated for angina (6.7% vs 12.4%).  However, after 
calculating the likelihood of attaining these cardiovascular outcomes and adjusting for 
baseline characteristics and treatment arm, there was no significant difference in CHD, 
between participants in Q1 and Q5 (HR, 0.93; 95% CI, 0.78-1.11) (Table 9). Moreover, 
 County Income Level Low Income Effect 
Outcome Q1 
% with BP <140/90 mmHg 
Q5 
% with BP <140/90 mmHg 
Risk-Adjusted ORA 
OR (95% CI) 
Year 1 44.8 57.3 0.63 (0.57, 0.70) 
Year 2 45.2 59.6 0.58 (0.52, 0.66) 
Year 3 48.1 63.6 0.55 (0.49, 0.63) 
Year 4 50.2 67.1 0.53 (0.46, 0.60) 
Year 5 51.2 68.0 0.52 (0.44, 0.63) 
Year 6 50.0 69.3 0.48 (0.36, 0.62) 
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after risk adjustments were made, participants in Q1 experienced significantly higher all-
cause mortality (HR, 1.25; 95% CI, 1.10-1.41), heart failure hospitalization/mortality 
(HR, 1.26; 95% CI, 1.03-1.55) and ESRD (HR, 1.86; 95% CI, 1.26-2.73). Participants in 
Q1 also had lower likelihood of angina treatment/hospitalization (HR, 0.70; 95% CI, 
0.59-0.83), combined CVD (HR, 0.89; 95% CI, 0.81-0.99) and coronary 
revascularization (HR, 0.71; 95% CI, 0.57-0.89). There were no significant differences in 
combined CHD, stroke, diagnosis of new onset heart failure, or peripheral arterial 
disease.  
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Table 8A. Adverse time-to-event unadjusted cardiovascular outcomes, for all treatment 
groups combined, separated by income level 
 County Income Level 
Outcome Q1 
N (%) 
Q2 
N (%) 
Q3 
N (%) 
Q4 
N (%) 
Q5 
N (%) 
Primary outcome      
 CHDA 150 (6.9) 374 (10.5) 494 (10.0) 699 (10.4) 1000 (9.6) 
Secondary Outcomes      
 All-cause mortality 342 (15.8) 596 (16.7) 833 (16.9) 1066 (15.9) 1571 (15.0) 
 Combined CHDB 264 (12.2) 631 (17.7) 932 (19.0) 1269 (18.9) 1868 (17.9) 
 Stroke 107 (4.9) 220 (6.2) 247 (5.0) 332 (4.9) 492 (4.7) 
 Combined CVDC 475 (21.9) 1065 (29.9) 1521 (30.9) 1987 (29.6) 3077 (29.4) 
Components of secondary outcomes      
 Heart Failure 140 (6.5) 290 (8.1) 358 (7.3) 522 (7.8) 739 (7.1) 
 Hospitalized/fatal heart failure 125 (5.8) 218 (6.1) 290 (5.9) 447 (6.7) 572 (5.5) 
 AnginaD 146 (6.7) 379 (10.6) 632 (12.9) 825 (12.3) 1299 (12.4) 
 Coronary revascularization 91 (4.2) 275 (7.7) 469 (9.5) 625 (9.3) 909 (8.7) 
 Peripheral arterial diseaseE,F,G 48 (2.2) 153 (4.3) 209 (4.3) 204 (3.0) 397 (3.8) 
 ESRD 38 (1.8) 62 (1.7) 62 (1.3) 130 (1.9) 120 (1.1) 
Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; N, number of 
participants; CHD, coronary heart disease; CVD, cardiovascular disease; ESRD, end-
stage renal disease. 
 
A CHD: fatal CHD or nonfatal MI combined. 
B Combined CHD: Fatal CHD, coronary revascularization, hospitalized angina. 
C Combined CVD: Combined CHD, stroke, other treated angina, HF, and peripheral 
artery disease. 
D Angina includes both hospitalized and treated angina. 
E Peripheral arterial disease (PAD) includes both hospitalized and treated PAD. 
F The following secondary outcomes are not included in this table: cancer, hospitalized 
for GI bleeding. 
G The following component of secondary outcomes was not included in this table: angina 
(hospitalized). 
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Table 8B. Adverse cardiovascular outcomes for chlorthalidone treatment arm 
Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; N, number of 
participants; CHD, coronary heart disease; CVD, cardiovascular disease; ESRD, end-
stage renal disease. 
 
A CHD: fatal CHD or nonfatal MI combined. 
B Combined CHD: Fatal CHD, coronary revascularization, hospitalized angina. 
C Combined CVD: Combined CHD, stroke, other treated angina, HF, and peripheral 
artery disease. 
D Angina includes both hospitalized and treated angina. 
E Peripheral arterial disease (PAD) includes both hospitalized and treated PAD. 
F The following secondary outcomes are not included in this table: cancer, hospitalized 
for GI bleeding. 
G The following component of secondary outcomes was not included in this table: angina 
(hospitalized). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 County Income Level 
Outcome Q1 
N (%) 
Q2 
N (%) 
Q3 
N (%) 
Q4 
N (%) 
Q5 
N (%) 
Primary outcome 
 CHDA  74 (7.4) 162 (10.0) 225 (10.0) 327 (10.6) 468 (9.8) 
Secondary Outcomes 
 All-cause mortality 171 (17.2) 270 (16.6) 378 (16.8) 498 (16.2) 734 (15.4) 
 Combined CHDB  125 (12.6) 275 (16.9) 428 (19.0) 567 (18.4) 860 (18.0) 
 Stroke 49 (4.9) 89 (5.5) 94 (4.2) 160 (5.2) 231 (4.8) 
 Combined CVDC  214 (21.5) 451 (27.8) 694 (30.8) 883 (28.7) 1374 (28.8) 
Components of secondary outcomes 
 Heart Failure 54 (5.4) 112 (6.9) 162 (7.2) 216 (7.0) 276 (5.8) 
 Hospitalized/fatal heart failure 48 (4.8) 83 (5.1) 135 (6.0) 188 (6.1) 224 (4.7) 
 AnginaD  64 (6.4) 172 (10.6) 287 (12.7) 358 (11.6) 578 (12.1) 
 Coronary revascularization 46 (4.6) 115 (7.1) 206 (9.1) 271 (8.8) 399 (8.4) 
 Peripheral arterial diseaseE  19 (1.9) 73 (4.5) 105 (4.7) 96 (3.1) 183 (3.8) 
 ESRDF,G 16 (1.6) 20 (1.2) 30 (1.3) 65 (2.1) 53 (0.9) 
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Table 8C. Adverse cardiovascular outcomes for amlodipine treatment arm 
 County Income Level 
Outcome Q1 
N (%) 
Q2 
N (%) 
Q3 
N (%) 
Q4 
N (%) 
Q5 
N (%) 
Primary outcome 
 CHDA  41 (7.0) 107 (11.1) 136 (10.2) 203 (11.2) 248 (8.7) 
Secondary Outcomes 
 All-cause mortality 85 (14.5) 159 (16.4) 221 (16.6) 284 (15.7) 417 (14.6) 
 Combined CHDB 68 (11.6) 173 (17.9) 256 (19.2) 363 (20.1) 483 (16.9) 
 Stroke 31 (5.3) 50 (5.2) 64 (4.8) 88 (4.9) 123 (4.3) 
 Combined CVDC 128 (21.8) 292 (30.2) 412 (30.9) 558 (30.9) 833 (29.2) 
Components of secondary outcomes 
 Heart Failure 45 (7.7) 99 (10.2) 106 (8.0) 106 (9.0) 239 (8.4) 
 Hospitalized/fatal heart failure 41 (7.0) 78 (8.1) 85 (6.5) 142 (7.9) 184 (6.5) 
 AnginaD 38 (6.5) 100 (10.3) 168 (12.6) 230 (12.7) 349 (12.2) 
 Coronary revascularization 27 (4.6) 77 (8.0) 136 (10.2) 179 (9.9) 251 (8.8) 
 Peripheral arterial diseaseE 14 (2.4) 35 (3.6) 48 (3.6) 52 (2.9) 99 (3.5) 
 ESRDF,G 12 (2.0) 26 (2.7) 15 (1.1) 31 (1.7) 36 (1.3) 
Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; N, number of 
participants; CHD, coronary heart disease; CVD, cardiovascular disease; ESRD, end-
stage renal disease. 
 
A CHD: fatal CHD or nonfatal MI combined. 
B Combined CHD: Fatal CHD, coronary revascularization, hospitalized angina. 
C Combined CVD: Combined CHD, stroke, other treated angina, HF, and peripheral 
artery disease. 
D Angina includes both hospitalized and treated angina. 
E Peripheral arterial disease (PAD) includes both hospitalized and treated PAD. 
F The following secondary outcomes are not included in this table: cancer, hospitalized 
for GI bleeding. 
G The following component of secondary outcomes was not included in this table: angina 
(hospitalized). 
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Table 8D. Adverse cardiovascular outcomes for lisinopril treatment arm 
 County Income Level 
Outcome Q1 
N (%) 
Q2 
N (%) 
Q3 
N (%) 
Q4 
N (%) 
Q5 
N (%) 
Primary outcome 
 CHDA  35 (6.0) 105 (10.8) 133 (10.0) 169 (9.2) 284 (10.0) 
Secondary Outcomes 
 All-cause mortality 86 (14.6) 167 (17.2) 234 (17.6) 284 (15.5) 420 (14.8) 
 Combined CHDB  71 (12.1) 183 (18.9) 248 (18.7) 339 (18.5) 525 (18.5) 
 Stroke 27 (4.6) 81 (8.4) 89 (6.7) 84 (4.6) 138 (4.9) 
 Combined CVDC  133 (22.6) 322 (33.2) 415 (31.2) 546 (29.7) 870 (30.7) 
Components of secondary outcomes 
 Heart Failure 41 (7.0) 79 (8.1) 90 (6.8) 143 (7.8) 224 (7.9) 
 Hospitalized/fatal heart failure 36 (6.1) 57 (5.9) 69 (5.2) 117 (6.4) 164 (5.8) 
 AnginaD  44 (7.5) 107 (11) 177 (13.3) 237 (12.9) 372 (13.1) 
 Coronary revascularization 18 (3.1) 83 (8.6) 127 (9.6) 175 (9.5) 259 (9.1) 
 Peripheral arterial diseaseE 15 (2.6) 45 (4.6) 56 (4.2) 56 (3.0) 115 (4.1) 
 ESRDF,G 10 (1.7) 16 (1.6) 17 (1.3) 34 (1.9) 41 (1.4) 
Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; N, number of 
participants; CHD, coronary heart disease; CVD, cardiovascular disease; ESRD, end-
stage renal disease. 
 
A CHD: fatal CHD or nonfatal MI combined. 
B Combined CHD: Fatal CHD, coronary revascularization, hospitalized angina. 
C Combined CVD: Combined CHD, stroke, other treated angina, HF, and peripheral 
artery disease. 
D Angina includes both hospitalized and treated angina. 
E Peripheral arterial disease (PAD) includes both hospitalized and treated PAD. 
F The following secondary outcomes are not included in this table: cancer, hospitalized 
for GI bleeding. 
G The following component of secondary outcomes was not included in this table: angina 
(hospitalized). 
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Table 9. Association between income and cardiovascular outcomes across income strata 
 County Income Level Low Income Effect 
Outcome Q1 
Incidence, % 
Q5 
Incidence, % 
Risk-Adjusted HRA 
HR (95% CI) 
Primary outcome 
 CHDB 6.9 9.6 0.93 (0.78-1.11) 
Secondary outcomes 
 All-cause mortality 15.8 15.0 1.25 (1.10-1.41) 
 Combined CHDC 12.2 17.9 0.89 (0.78-1.01) 
 Stroke 4.9 4.7 1.16 (0.93-1.45) 
 Combined CVDD 21.9 29.4 0.89 (0.81-0.99) 
Components of secondary outcomes 
 Heart Failure 6.5 7.1 1.07 (0.88-1.29) 
 Hospitalized/fatal heart failure 5.8 5.5 1.26 (1.03-1.55) 
 AnginaE 6.7 12.4 0.70 (0.59-0.83) 
 Coronary revascularization 4.2 8.7 0.71 (0.57-0.89) 
 Peripheral arterial diseaseF 2.2 3.8 0.87 (0.64-1.18) 
 ESRDG,H 1.8 1.1 1.86 (1.26-2.73) 
Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; HR, hazard 
ratio; CI, confidence interval; CHD, coronary heart disease; CVD, cardiovascular 
disease; ESRD, end-stage renal disease.  
 
A Risk-adjusted hazard ratios represent likelihood of having an adverse cardiovascular 
event, with the highest income quintile, Q5, serving as the reference group. Model adjusts 
for treatment group, age, sex, baseline SBP and DBP, and qualifying risk factors for 
ALLHAT (BMII, history of MI or stroke, history of coronary revascularization, history of 
CHD at baseline, other ASCVD, participation in lipid-lowering trial, type II diabetes, 
history of major ST depression or T-wave inversionI, aspirin use, HDL-C < 35 mg/dL, 
LVH by ECG, LVH by echocardiogramI, cigarette smokingI, and estrogen 
supplementationI).  
B CHD: fatal CHD or nonfatal MI combined. 
C Combined CHD: Fatal CHD and nonfatal MI combined, coronary revascularization, 
hospitalized angina. 
D Combined CVD: Combined CHD, stroke, other treated angina, HF, and peripheral 
artery disease. 
E Angina includes both hospitalized and treated angina. 
F Peripheral arterial disease (PAD) includes both hospitalized and treated PAD. 
G The following secondary outcomes from ALLHAT are not included: cancer, 
hospitalized for GI bleeding. 
H The following components of secondary outcomes was not included in this table: 
angina (hospitalized). 
I A minority of study participants have missing values for these risk factors. The missing 
values for these participants were imputed. 
 
Among black participants, those in Q1 still had higher all-cause mortality after 
risk adjustment (HR, 1.24; 95% CI, 1.06-1.44), and greater (although not significant) 
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hospitalized/fatal heart failure (HR, 1.29; 95% CI, 0.99-1.68) and ESRD (HR, 1.47; 95% 
CI, 0.91-2.36). They also had lower angina treatment/hospitalization (HR, 0.69; 95% CI, 
0.55-0.87) and coronary revascularization (HR, 0.69; 95% CI, 0.48-0.99) (Table 10A). 
There were no significant differences between income groups among black participants 
for other outcomes, including CHD, combined CHD, stroke, combined CVD, new-onset 
heart failure, or peripheral arterial disease. Among participants in the South, the risk of 
adverse cardiovascular outcomes followed similar trends as the overall study population 
(Table 10B). Southern participants in Q1 were more likely to experience all-cause 
mortality (HR, 1.14; 95% CI, 0.96-1.36) and ESRD (HR, 1.57; 95% CI, 0.87-2.82), and 
less likely to have angina (HR, 0.81; 95% CI, 0.64-1.03) and receive coronary 
revascularization (HR, 0.76; 95% CI, 0.57-1.01). However, none of these findings were 
statistically significant.  
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Table 10A. Association between income and time to cardiovascular outcomes among 
black ALLHAT participants across socioeconomic strata 
 County Income Level Low Income Effect 
Outcome Q1 
Incidence, % 
Q5 
Incidence, % 
Risk-Adjusted HRA 
HR (95% CI) 
Primary outcome 
 CHDB 7.0 8.5 0.90 (0.71-1.14) 
Secondary outcomes 
 All-cause mortality 17.8 15.9 1.24 (1.06-1.44) 
 Combined CHDC 11.2 14.4 0.89 (0.74-1.07) 
 Stroke 5.2 5.5 1.07 (0.81-1.41) 
 Combined CVDD 22.1 26.8 0.90 (0.79-1.03) 
Components of secondary outcomes 
 Heart Failure 6.9 6.7 1.18 (0.92-1.50) 
 Hospitalized/fatal heart failure 6.0 5.3 1.29 (0.99-1.68) 
 AnginaE 6.3 10.3 0.69 (0.55-0.87) 
 Coronary revascularization 2.8 4.8 0.69 (0.48-0.99) 
 Peripheral arterial diseaseF 2.1 3.3 0.75 (0.49-1.13) 
 ESRDG,H 2.0 1.6 1.47 (0.91-2.36) 
Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; HR, hazard 
ratio; CI, confidence interval; CHD, coronary heart disease; CVD, cardiovascular 
disease; ESRD, end-stage renal disease.  
 
A Risk-adjusted hazard ratios represent likelihood of having an adverse cardiovascular 
event, with the highest income quintile, Q5, serving as the reference group. Model adjusts 
for treatment group, age, sex, baseline SBP and DBP, and qualifying risk factors for 
ALLHAT (BMII, history of MI or stroke, history of coronary revascularization, history of 
CHD at baseline, other ASCVD, participation in lipid-lowering trial, type II diabetes, 
history of major ST depression or T-wave inversionI, aspirin use, HDL-C < 35 mg/dL, 
LVH by ECG, LVH by echocardiogramI, cigarette smokingI, and estrogen 
supplementationI).  
B CHD: fatal CHD or nonfatal MI combined. 
C Combined CHD: Fatal CHD and nonfatal MI combined, coronary revascularization, 
hospitalized angina. 
D Combined CVD: Combined CHD, stroke, other treated angina, HF, and peripheral 
artery disease. 
E Angina includes both hospitalized and treated angina. 
F Peripheral arterial disease (PAD) includes both hospitalized and treated PAD. 
G The following secondary outcomes from ALLHAT are not included: cancer, 
hospitalized for GI bleeding. 
H The following component of secondary outcomes was not included in this table: angina 
(hospitalized). 
I A minority of study participants have missing values for these risk factors. The missing 
values for these participants were imputed. 
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Table 10B. Association between income and time to cardiovascular event outcomes 
among participants in ALLHAT living in the South across socioeconomic strata 
 County Income Level Low Income Effect 
Outcome Q1 
Incidence, % 
Q5 
Incidence, % 
Risk-Adjusted HRA 
HR (95% CI) 
Primary outcome 
 CHDB 6.8 9.0 0.94 (0.73-1.19) 
Secondary outcomes 
 All-cause mortality 15.8 14.7 1.14 (0.96-1.36) 
 Combined CHDC 12.1 16.4 0.94 (0.78-1.13) 
 Stroke 5.0 4.2 1.22 (0.89-1.68) 
 Combined CVDD 21.8 26.7 0.92 (0.80-1.06) 
Components of secondary outcomes 
 Heart Failure 6.4 7.3 0.93 (0.71-1.20) 
 Hospitalized/fatal heart failure 5.8 5.7 1.09 (0.82-1.45) 
 AnginaE 6.7 10.5 0.81 (0.64-1.03) 
 Coronary revascularization 4.3 8.1 0.76 (0.57-1.01) 
 Peripheral arterial diseaseF 2.2 3.3 1.02 (0.68-1.55) 
 ESRDG,H 1.7 1.1 1.57 (0.87-2.82) 
Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; HR, hazard 
ratio; CI, confidence interval; CHD, coronary heart disease; CVD, cardiovascular 
disease; ESRD, end-stage renal disease.  
 
A Risk-adjusted hazard ratios represent likelihood of having an adverse cardiovascular 
event, with the highest income quintile, Q5, serving as the reference group. Model adjusts 
for treatment group, age, sex, baseline SBP and DBP, and qualifying risk factors for 
ALLHAT (BMII, history of MI or stroke, history of coronary revascularization, history of 
CHD at baseline, other ASCVD, participation in lipid-lowering trial, type II diabetes, 
history of major ST depression or T-wave inversionI, aspirin use, HDL-C < 35 mg/dL, 
LVH by ECG, LVH by echocardiogramI, cigarette smokingI, and estrogen 
supplementationI).  
B CHD: fatal CHD or nonfatal MI combined. 
C Combined CHD: Fatal CHD and nonfatal MI combined, coronary revascularization, 
hospitalized angina. 
D Combined CVD: Combined CHD, stroke, other treated angina, HF, and peripheral 
artery disease. 
E Angina includes both hospitalized and treated angina. 
F Peripheral arterial disease (PAD) includes both hospitalized and treated PAD. 
G The following secondary outcomes from ALLHAT are not included: cancer, 
hospitalized for GI bleeding. 
H The following component of secondary outcomes was not included in this table: angina 
(hospitalized). 
I A minority of study participants have missing values for these risk factors. The missing 
values for these participants were imputed. 
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In exploratory analyses adjusting for visit adherence, results also followed similar 
trends, but all-cause mortality (HR, 1.03; 95% CI, 0.91-1.16) and heart failure 
treatment/hospitalizations (HR, 1.19; 95% CI, 0.97-1.46) were no longer significantly 
greater among Q1 participants (Table 11). Other outcomes were unchanged from the 
main findings. ESRD was still significantly higher among Q1 participants (HR, 1.70; 
95% CI, 1.16-2.51). As before, participants in Q1 were less likely to have angina (HR, 
0.69; 95% CI, 0.58-0.83) and receive coronary revascularization (HR, 0.70; 95% CI, 
0.56-0.88). 
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Table 11. Association between income and time to cardiovascular event outcomes across 
economic strata, adjusted for visit adherence 
 County Income Level Low Income Effect 
Outcome Q1 
Incidence, % 
Q5 
Incidence, % 
Risk-Adjusted HRA 
HR (95% CI) 
Primary outcome 
 CHDB 6.9 9.6 0.87	(0.72,1.04)	
Secondary outcomes 
 All-cause mortality 15.8 15.0 1.03	(0.91,1.16)	
 Combined CHDC 12.2 17.9 0.85	(0.74,0.97)	
 Stroke 4.9 4.7 1.06	(0.85,1.32)	
 Combined CVDD 21.9 29.4 0.86	(0.78,0.95)	
Components of secondary outcomes 
 Heart Failure 6.5 7.1 1.01	(0.84,1.23)	
 Hospitalized/fatal heart failure 5.8 5.5 1.19	(0.97,1.46)	
 AnginaE 6.7 12.4 0.69	(0.58,0.83)	
 Coronary revascularization 4.2 8.7 0.70	(0.56,0.88)	
 Peripheral arterial diseaseF 2.2 3.8 0.86	(0.63,1.17)	
 ESRDG,H 1.8 1.1 1.70	(1.16,2.51)	
Abbreviations: Q1, lowest income quintile; Q5, highest income quintile; HR, hazard 
ratio; CI, confidence interval; CHD, coronary heart disease; CVD, cardiovascular 
disease; ESRD, end-stage renal disease.  
 
A Risk-adjusted hazard ratios represent likelihood of having an adverse cardiovascular 
event, with the highest income quintile, Q5, serving as the reference group. Model adjusts 
for treatment group, age, sex, baseline SBP and DBP, qualifying risk factors for 
ALLHAT (BMIi, history of MI or stroke, history of coronary revascularization, history of 
CHD at baseline, other ASCVD, participation in lipid-lowering trial, type II diabetes, 
history of major ST depression or T-wave inversioni, aspirin use, HDL-C < 35 mg/dL, 
LVH by ECG, LVH by echocardiogrami, cigarette smokingi, and estrogen 
supplementationi), and six year visit adherencei.  
B CHD: fatal CHD or nonfatal MI combined. 
C Combined CHD: Fatal CHD and nonfatal MI combined, coronary revascularization, 
hospitalized angina. 
D Combined CVD: Combined CHD, stroke, other treated angina, HF, and peripheral 
artery disease. 
E Angina includes both hospitalized and treated angina. 
F Peripheral arterial disease (PAD) includes both hospitalized and treated PAD. 
G The following secondary outcomes from ALLHAT are not included: cancer, 
hospitalized for GI bleeding. 
H The following components of secondary outcomes was not included in this table: 
angina (hospitalized). 
I A minority of study participants have missing values for these risk factors. The missing 
values for these participants were imputed. 
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Discussion 
 
In a large, nationally dispersed RCT of antihypertensive therapy, we observed 
significant variation in blood pressure control and cardiovascular outcomes according to 
the socioeconomic context in which clinical care was provided. Participants receiving 
care in the lowest income sites as compared with the highest income sites had 
significantly worse blood pressure control with antihypertensive medications, irrespective 
of medication study arm, and higher rates of heart failure hospitalizations, ESRD and 
mortality, even after adjusting for demographic and clinical characteristics. These 
disparities persisted in subgroup analyses of black participants and those living in the 
South, populations that have previously been shown to have worse hypertension-
associated cardiovascular outcomes, demonstrating that socioeconomic context is 
independently important.  
Although the impact of socioeconomic context on health outcomes is known, the 
differences in clinical outcomes in this study are notable because they occurred in the 
context of a large RCT, which typically affords participants equal access to health care 
resources by 1) assigning them to standardized protocols in which study medications are 
provided free-of-charge, and 2) providing specific guidelines for the intensification of 
medication and provision of follow-up visits. Moreover, although ALLHAT enrolled a 
geographically and ethnically diverse population, only 8% of participants came from the 
lowest income sites, whereas 38% came from the highest income sites, potentially 
reducing the generalizability of trial findings to low socioeconomic populations and 
opportunities to more fully understand the disparities observed in this analysis.  
 51 
The association between sociodemographic characteristics and hypertension is 
already well-documented. Studies have shown that improvement in cardiovascular risk 
factors over recent decades in the U.S. have disproportionately occurred among adults of 
higher socioeconomic strata (14, 109). Moreover, RCTs of pharmacologic interventions 
for hypertension have demonstrated an effect of person-level demographic factors, such 
as race, gender and income, on cardiovascular outcomes, though not of community-level 
factors (83, 85, 99, 104, 110). However, to date no studies have examined the influence 
of socioeconomic context on outcomes resulting from antihypertensive treatment. While 
the relationships between person-level factors and hypertension outcomes are important 
to understand and address, inattention to the effect of community-level factors related to 
socioeconomic context may obscure data that are important for achieving improved 
cardiovascular outcomes.  
Specifically, the differences in outcomes we report here may be a result of 
differences in any number of factors: a community’s health behaviors (e.g., diet, exercise, 
smoking, and alcohol trends), clinical factors (e.g., access to care, quality of care, visit 
adherence, or medication adherence), or other aspects of the physical and social 
environment (e.g., housing, access to healthy foods and exercise, neighborhood violence, 
social cohesion), all of which may impact pharmacoeffectiveness. The disparities we 
observed may also indicate that despite the efforts of RCTs to standardize treatment 
protocols, clinical sites in low-resource areas may have fewer overall resources and 
capabilities than those in wealthier areas. Unfortunately, existing methods are limited in 
their ability to isolate the impact of these other factors on clinical outcomes in RCTs. To 
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rectify this problem, future clinical trials could attempt to explicitly measure these 
factors. 
Notably, participants in the lowest income sites had lower visit adherence than 
those in the highest income sites, though the reasons for this are uncertain. Visit 
adherence may have a direct effect on outcomes, wherein attending visits more frequently 
provides more opportunities to improve outcomes. Additionally, factors associated with 
adherence to visits (e.g. access to transportation, health behaviors, physician-patient 
relationship) may indirectly impact outcomes. Our exploratory analysis adjusting for six 
year visit adherence supports the possibility that fidelity to the protocol may explain 
some of the difference in outcomes between the two groups. However, differences in 
blood pressure control were unchanged even after adjusting for visit adherence. In 
addition, visit and medication adherence were actually highest in the second-lowest 
income quintile, making it difficult to determine to what extent adherence varies by 
socioeconomic context. Regrettably, in this study, medication adherence was 
inadequately assessed and was missing in up to 1/3 of participants, limiting interpretation 
of findings. Ultimately, to fully understand the importance of adherence on outcomes in 
clinical trials, more rigorous and complete assessment of adherence is needed, especially 
to the study medication.  
Potentially related, participants in the lowest income sites were significantly less 
likely to receive coronary revascularization, or be hospitalized or treated for angina. An 
aggregate outcome, combined CVD (which contains coronary revascularization and 
angina as subcomponents) was also less likely among participants in the lowest income 
sites. These findings were contrary to our hypothesis that socioeconomic context could 
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lead to greater cardiovascular morbidity and related procedural interventions. However, 
given the racial and socioeconomic make-up of participants in low income sites, it is 
plausible that these findings reflect differences in presentation by race (111) or in 
utilization patterns related to cultural norms for seeking care, access to care, or other 
unmeasured factors. Numerous studies have previously shown that patients who are black 
or of lower socioeconomic status are less likely to receive procedures such as coronary 
revascularization (112-114). Unfortunately, in this study design we are not able to discern 
whether these outcomes are measuring the effect of true differences in cardiovascular 
events or differences in access to or quality of care beyond the standardized protocol of 
the trial. 
Furthermore, we noted a substantial difference in blood pressure control, visit and 
medication adherence, coronary revascularization, and hospitalized or treated angina 
between the lowest income quintile and the other four income quintiles, which tended to 
have greater similarities in outcomes. The median household income in the lowest 
income quintile was $21,800; by comparison, the federal poverty level – the threshold or 
minimum level of income one would need to secure the necessities of life – for a family 
of 4 was $17,050 in the year 2000 (115). This suggests that participants in the lowest 
income sites obtained care (and potentially lived) in some of the poorest counties in the 
United States, where many people may not have access to sufficient resources to secure 
these basic necessities. Similar to the federal poverty level, there may exist a threshold of 
resources that a community must surpass in order for its inhabitants to be able to live and 
maintain their health or well-being, and thus achieve hypertension outcomes similar to 
those of less deprived communities. Although the existing literature has been unable to 
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shed further light on this question, the relationship between area-level socioeconomic 
deprivation and hypertension outcomes is likely more nuanced, in that different 
communities may require different resources in order to thrive. 
In addition, we attempted to separate the effects of race from socioeconomic 
context by assessing socioeconomic groups within racial strata and found that the results 
did not differ from the overall findings; however, participants in the lowest income sites 
were more likely to be black, making it difficult to fully distinguish any association of 
race with cardiovascular outcomes. Genetic factors may contribute to racial disparities in 
these outcomes. For example, participants in the lowest income sites, many of whom 
were minorities, had significantly higher risk for ESRD. Genetic studies have 
demonstrated that there is a higher prevalence of a high-risk variant of the apoliprotein L-
1 (APOL1) gene in African-American populations, as compared to European-American 
populations (116). The presence of this allele is associated with a higher risk of end-stage 
kidney disease attributed to hypertension. Differences in clinical characteristics may also 
play a role. Previous studies have shown that black participants are less likely to achieve 
blood pressure control, even in the context of RCTs (including ALLHAT), possibly due 
to difference in medication and visit adherence (85, 110, 117-119). Such racial disparities 
in outcomes are well documented for other cardiovascular conditions, as well, with some 
studies identifying economic and social barriers affecting blood pressure control in black 
patients (60, 120-122). One such factor, residential neighborhood segregation has been 
associated with changes in systolic blood pressure, indicating that there may be overlap 
between individual factors such as race and contextual factors such as disparate 
household incomes within a community (123).  
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Additionally, structural racism leading to increased stress exposure and reactivity, 
along with differences in quality of care may impact outcomes, though are seldom 
assessed in RCTs (124). The United States has a long history of socioeconomic and racial 
disparities, and there may be shared or unique structural disparities leading to these 
differences that we may not be able to capture, given the limitations of existing clinical 
trial data. Thus, other methodological approaches may be necessary to better and more 
rigorously encapsulate the effect of these complex and interrelated disparities on health 
outcomes. 
 Geographic location may also be important. Nearly all participants in the lowest 
income sites lived in the South, consistent with studies dating back as far as the 1980s 
which have shown that poverty rates have historically been higher in the South than in 
the rest of the country (125). Prior studies from ALLHAT demonstrate that living in the 
South predicted a lower likelihood of achieving blood pressure control as compared with 
other U.S. and non-U.S. regions (85). This finding is consistent with a recent CDC report 
that indicated worse hypertension control in Southern states thought to be part of the 
“stroke belt” (119). Another secondary analysis of ALLHAT found that there were no 
statistically significant differences in medication adherence among patients based on the 
geographic region in which their clinical site was located (117). However, both of these 
studies considered broad geographic regions encompassing many counties, rather than 
singular counties. Other studies of hypertension and cardiovascular RCTs have evaluated 
the effect of geographic region on study outcomes, but these studies were conducted at 
the country level or at similarly broad regional geographic levels, potentially obscuring 
heterogeneity within large geographic areas (126-135). Moreover, many RCTs do not 
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enroll enough patients to be able to study geographic effect at a more granular level. Still, 
these studies are consistent with our findings and demand that more work be done to 
understand the nature of regional disparities in hypertension outcomes, which persist 
even within large, robust RCTs. 
 
Limitations 
There are several limitations to this study. First, it is possible that the county in 
which a clinical site is located may differ from a participant’s county of residence. While 
distance from residence to medical care varies by rurality, in an RCT, we assumed that 
people who decided to participate in the study would live reasonably close. More 
importantly, counties differ in size and may comprise several socioeconomic contexts; 
though we did not have data to study the effect of socioeconomic context at a more 
granular level (such as census tract), our use of county level measures would tend to bias 
our findings towards the null, as it dilutes the true income status of a community. Third, 
area income may not be a perfect indicator of social risk factors, such as neighborhood 
violence or access to healthy foods, which can impact health outcomes. However, 
county-level analyses can serve as a reasonable proxy for the amount of resources 
available in a community and can be important for directing policy interventions and 
resources.  
Fourth, though it is the largest completed randomized hypertension trial, the data 
from ALLHAT is now nearly 20 years old and progress may have been made in the 
interim in addressing disparities in hypertension outcomes. Fifth, although the population 
enrolled in ALLHAT was indeed socio-demographically and geographically diverse, only 
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12% of U.S. counties were represented by the clinical sites in this study, potentially 
limiting the generalizability of our findings. Sixth, although we performed subgroup 
analyses for black participants and those living in the South, we were unable to perform 
similar stratified analyses for participants of other races or those living in other regions. 
This was due to an insufficient number of participants with these identifiers in either the 
top or bottom income quintiles. Given that clinical sites in the South were more likely to 
be low income and enroll black participants, we may not have been able to fully discern 
the effects of race and geography from socioeconomic context.  Seventh, because we did 
not have access to unique location or clinic identifiers for each patient, we were unable to 
account for correlation of outcomes within an area. Though this may have resulted in 
overnarrow confidence intervals, none of our key findings were marginal and thus it is 
reasonable to expect that they would have been unchanged even if we had accounted for 
such correlation. Last, data on medication adherence was insufficient to include in our 
secondary analyses, making it more difficult to delineate the extent to which medication 
adherence may have attenuated outcomes. However, medication adherence was likely 
influenced by contextual factors which were not measured in this trial.  
 
Conclusions 
Observational studies have previously shown that socioeconomic context is 
associated with hypertension and worse hypertension outcomes. This study extends these 
findings to the largest randomized clinical trial of antihypertensive treatment, in which 
participants had equal access to resources afforded by such a trial. Although participants 
across income strata were appropriately randomized to the main treatment arms, we 
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observed disparities in participant characteristics and visit and medication adherence 
across socioeconomic strata, and found that study enrollment favored participants from 
higher socioeconomic strata. We also observed disparities in blood pressure control, heart 
failure morbidity, ESRD, all-cause mortality and coronary revascularization across 
socioeconomic strata, even after controlling for medication treatment arm, demographics, 
and clinical characteristics; furthermore, there may be some suggestion that visit 
adherence may have impacted outcomes. 
These results bring into question whether the anticipated benefits of 
antihypertensive therapy, derived from landmark trials such as ALLHAT, are truly 
generalizable to all communities within the U.S. The heterogeneity in treatment effect by 
socioeconomic context observed in this study is important knowledge because it may 
have implications for guideline recommendations and clinical decision making. Our 
findings thus underscore the importance of measuring socioeconomic context in RCTs 
and suggest the need to develop better methods to capture contextual data and understand 
their association with outcomes, so that findings from clinical trials can inform treatment 
guidelines and also be generalized to populations encountered in everyday clinical 
practice.  
Moreover, to attain equity in hypertension outcomes, we must not only work to 
implement guideline recommendations for antihypertensive therapy, but we must also 
work within communities to address the underpinnings of disparities by socioeconomic 
context. In the context of RCTs, investigators of future trials of antihypertensive 
medications should make more concerted efforts to recruit socioeconomically diverse 
participants or offer additional resources to participants in disadvantaged areas to 
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eliminate disparities in trial outcomes and ensure that study results are meaningful for 
these populations. In clinical practice, physicians could offer additional support or 
resources to patients from under-resourced communities seeking treatment for 
hypertension; physicians and researchers might encourage elected leaders and 
professional societies at the local, state, and federal levels to focus on contextual factors 
impacting cardiovascular outcomes. For example, public policy efforts and grants could 
focus on addressing the underlying factors that disproportionally affect low 
socioeconomic communities today and which may relate to hypertension and 
cardiovascular outcomes, including improving local infrastructure to support exercise and 
access to healthy foods, reduce stress, improve neighborhood safety, and increase access 
to medicines, primary care, mental health resources, and more. Finally, recognition of 
and sensitivity to the contextual socioeconomic factors influencing response to 
antihypertensive medication can support more effective, patient- and community-
centered approaches that go beyond the guidelines to manage hypertension.  
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